{"587659":{"#nid":"587659","#data":{"type":"news","title":"Raquel Lieberman Is Having A Great Year, and It\u2019s Only February","body":[{"value":"\u003Cp\u003E\u003Ca href=\u0022http:\/\/www.chemistry.gatech.edu\/faculty\/lieberman\/\u0022\u003ERaquel Lieberman,\u003C\/a\u003E associate professor at the School of Chemistry and Biochemistry, is having the Best. Winter. Ever.\u003C\/p\u003E\r\n\r\n\u003Cp\u003EThat is, as long as you don\u0026rsquo;t count that whole Super Bowl thing.\u003C\/p\u003E\r\n\r\n\u003Cp\u003ELieberman has started the year with excellent news: She\u0026rsquo;s been asked to serve on the academic editorial board of a major scientific journal, and she and her research team \u0026ndash; the Lieberman Lab - can continue their work on early-stage glaucoma, thanks to this month\u0026rsquo;s renewal of a $1.48 million National Institutes of Health (NIH) grant.\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u0026ldquo;We had known since June that the grant score we got was meritorious,\u0026rdquo; Lieberman says. \u0026ldquo;But you can\u0026rsquo;t count your chickens before they hatch.\u0026rdquo;\u003C\/p\u003E\r\n\r\n\u003Cp\u003EIf any birds have learned that the hard way, it\u0026rsquo;s the Atlanta Falcons. In the days before Super Bowl LI proved that point, Lieberman patiently waited to hear about her grant request.\u003C\/p\u003E\r\n\r\n\u003Cp\u003EHer spirits got a boost early this month when Georgia Tech\u0026rsquo;s \u003Ca href=\u0022http:\/\/www.osp.gatech.edu\/\u0022\u003EOffice of Sponsored Programs\u003C\/a\u003E \u0026ndash; the Institute\u0026rsquo;s support department for research administration \u0026ndash; told her it needed to do some budget updating. \u0026ldquo;Which is a good sign,\u0026rdquo; she says.\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u0026ldquo;But then the Falcons lost.\u0026rdquo;\u003C\/p\u003E\r\n\r\n\u003Cp\u003ELieberman was determined to not let that painful\u0026nbsp;collapse jinx her hopes or dampen her mood. Sure enough, the very next morning, Lieberman learned from NIH that she could continue her work and keep her staff of researchers employed for the next four years.\u003C\/p\u003E\r\n\r\n\u003Cp\u003EAfter the first five years of funding, \u0026ldquo;four more will be nine years straight of working on this exact same line of questioning, which is super, super gratifying,\u0026rdquo; she says. \u0026ldquo;We didn\u0026rsquo;t have anything in the beginning, just very basic observations. Because we were able to make important contributions to the field, NIH has given us more money to continue. That\u0026rsquo;s a huge milestone.\u0026rdquo;\u003C\/p\u003E\r\n\r\n\u003Cp\u003EThe path to success has included two advances in understanding glaucoma, a collection of eye diseases that make up the \u003Ca href=\u0022http:\/\/www.who.int\/bulletin\/volumes\/82\/11\/feature1104\/en\/\u0022\u003Esecond leading cause of blindness worldwide\u003C\/a\u003E.\u003C\/p\u003E\r\n\r\n\u003Cp\u003ELieberman\u0026rsquo;s Lab focuses on the protein myocilin. When the gene encoding for myocilin has a defect, the resulting mutant protein is toxic to the part of the eye responsible for controlling eye pressure. Mutant myocilin accumulates, preventing the easy flow of aqueous humor fluid and raising eye pressure, which can damage the optic nerve. Myocilin-associated glaucoma is hereditary and early-onset, affecting the vision of children and adults through approximately age 35, Lieberman says.\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u0026ldquo;If you gunk up the molecular sieve that lets fluid drain out of the eye, the pressure goes up,\u0026rdquo; Lieberman said. \u0026ldquo;This mutant protein kills the cells that are making sure that the sieve stays appropriately porous.\u0026rdquo;\u003C\/p\u003E\r\n\r\n\u003Cp\u003EIn 2014, the Lieberman Lab and collaborators at the University of Kansas and South Florida announced that they had \u003Ca href=\u0022https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25027323\u0022\u003Eidentified molecules that could serve as drugs to block the impact of mutant myocilin\u003C\/a\u003E. The next year, Lieberman\u0026rsquo;s lab announced it had \u003Ca href=\u0022https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25524706\u0022\u003Esolved the three-dimensional structure of a particular domain in myocilin \u0026ndash; the olfactomedin (OLF)\u003C\/a\u003E - that is tied to early-onset glaucoma.\u003C\/p\u003E\r\n\r\n\u003Cp\u003EOLF is where most of the protein mutations are documented in patients, and the new NIH grant will support studies that will help unlock more of myocilin\u0026rsquo;s mysteries.\u003C\/p\u003E\r\n\r\n\u003Cp\u003ELieberman\u0026rsquo;s fantastic February also includes the news that she\u0026rsquo;ll serve a three-year term as an academic editorial board member for \u003Cem\u003EPLoS (Public Library of Science) Biology.\u003C\/em\u003E The high-impact publication is known for spotlighting innovative research throughout the biological sciences. But before getting excited about the email inviting her to join \u003Cem\u003EPLoS Biology,\u003C\/em\u003E she had to make sure it was the real thing.\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u0026ldquo;Nowadays, if you\u0026rsquo;re an academic researcher, every morning you wake up to a lot of emails from people and entities you\u0026rsquo;ve never heard of inviting you to present at conferences or to submit manuscripts to journals. Because I get this spam all the time, I had to pause and realize this invitation was in fact the real deal.\u0026rdquo;\u003C\/p\u003E\r\n\r\n\u003Cp\u003ELieberman will be handling the review of up to two articles each month, setting up peer reviews and helping to determine whether they should be accepted or rejected.\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u0026ldquo;I have a lot of experience with rejection,\u0026rdquo; she jokes. \u0026ldquo;\u003Cem\u003EPLoS Biology\u003C\/em\u003E has high expectations,\u0026rdquo; she says, seriously. \u0026ldquo;We\u0026rsquo;ll see what comes down the pike. I\u0026rsquo;m very excited.\u0026rdquo;\u003C\/p\u003E\r\n\r\n\u003Cp\u003EIn her editorial role, Lieberman can also help fellow Georgia Tech researchers navigate the \u003Cem\u003EPLoS Biology\u003C\/em\u003E process for their own papers. \u0026ldquo;I want people around here to know that I can help facilitate their submissions,\u0026rdquo; she says. \u0026ldquo;I can\u0026rsquo;t officially be the editor for an article that\u0026rsquo;s from Georgia Tech, but I can help send them to somebody else.\u0026rdquo;\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u0026nbsp;\u003C\/p\u003E\r\n","summary":null,"format":"limited_html"}],"field_subtitle":[{"value":"Million-dollar grant renewal, invitation to PLoS Biology\u2019s board makes it a February to remember"}],"field_summary":[{"value":"\u003Cp\u003ERaquel Lieberman has started the year with excellent news: She\u0026rsquo;s been asked to serve on the academic editorial board of a major scientific journal, and she and her research team can continue their work on early-stage glaucoma, thanks to this month\u0026rsquo;s renewal of a $1.48 million National Institutes of Health (NIH) grant.\u003C\/p\u003E\r\n","format":"limited_html"}],"field_summary_sentence":[{"value":"Raquel Lieberman, associate professor at the School of Chemistry and Biochemistry, is having the Best. Winter. Ever. "}],"uid":"34434","created_gmt":"2017-02-20 21:53:09","changed_gmt":"2017-02-21 15:34:02","author":"Renay San Miguel","boilerplate_text":"","field_publication":"","field_article_url":"","dateline":{"date":"2017-02-20T00:00:00-05:00","iso_date":"2017-02-20T00:00:00-05:00","tz":"America\/New_York"},"extras":[],"hg_media":{"587444":{"id":"587444","type":"image","title":"Raquel Lieberman","body":null,"created":"1487107498","gmt_created":"2017-02-14 21:24:58","changed":"1487683948","gmt_changed":"2017-02-21 13:32:28","alt":"","file":{"fid":"223881","name":"Asso. Professor Raquel Lieberman.jpg","image_path":"\/sites\/default\/files\/images\/Asso.%20Professor%20Raquel%20Lieberman.jpg","image_full_path":"http:\/\/www.tlwarc.hg.gatech.edu\/\/sites\/default\/files\/images\/Asso.%20Professor%20Raquel%20Lieberman.jpg","mime":"image\/jpeg","size":76097,"path_740":"http:\/\/www.tlwarc.hg.gatech.edu\/sites\/default\/files\/styles\/740xx_scale\/public\/images\/Asso.%20Professor%20Raquel%20Lieberman.jpg?itok=HovnmW0m"}},"587662":{"id":"587662","type":"image","title":"The glaucoma-associated ofactomedin domain of myocilin normally exists as straight fibrils (left); mutation leads to a disease-causing variant forming large circular fibrils (right).  Courtesy of Raquel Lieberman. ","body":null,"created":"1487628024","gmt_created":"2017-02-20 22:00:24","changed":"1487628024","gmt_changed":"2017-02-20 22:00:24","alt":"","file":{"fid":"223964","name":"The glaucoma-associated ofactomedin domain of myocilin normally exists as straight fibrils (left); mutation leads to a disease-causing variant forming large circular fibrils (right).  Courtesy of Raquel Lieberman.jpg","image_path":"\/sites\/default\/files\/images\/The%20glaucoma-associated%20ofactomedin%20domain%20of%20myocilin%20normally%20exists%20as%20straight%20fibrils%20%28left%29%3B%20mutation%20leads%20to%20a%20disease-causing%20variant%20forming%20large%20circular%20fibrils%20%28right%29.%20%20Courtesy%20of%20Raquel%20Lieberman.jpg","image_full_path":"http:\/\/www.tlwarc.hg.gatech.edu\/\/sites\/default\/files\/images\/The%20glaucoma-associated%20ofactomedin%20domain%20of%20myocilin%20normally%20exists%20as%20straight%20fibrils%20%28left%29%3B%20mutation%20leads%20to%20a%20disease-causing%20variant%20forming%20large%20circular%20fibrils%20%28right%29.%20%20Courtesy%20of%20Raquel%20Lieberman.jpg","mime":"image\/jpeg","size":84445,"path_740":"http:\/\/www.tlwarc.hg.gatech.edu\/sites\/default\/files\/styles\/740xx_scale\/public\/images\/The%20glaucoma-associated%20ofactomedin%20domain%20of%20myocilin%20normally%20exists%20as%20straight%20fibrils%20%28left%29%3B%20mutation%20leads%20to%20a%20disease-causing%20variant%20forming%20large%20circular%20fibrils%20%28right%29.%20%20Courtesy%20of%20Raquel%20Lieberman.jpg?itok=OD2bDAym"}}},"media_ids":["587444","587662"],"groups":[{"id":"1278","name":"College of Sciences"},{"id":"85951","name":"School of Chemistry and Biochemistry"}],"categories":[{"id":"135","name":"Research"}],"keywords":[{"id":"4896","name":"College of Sciences"},{"id":"166928","name":"School of Chemistry and Biochemistry"},{"id":"10858","name":"Raquel Lieberman"},{"id":"173471","name":"PLOS Biology"},{"id":"365","name":"Research"},{"id":"17401","name":"Glaucoma"},{"id":"84701","name":"myocilin"},{"id":"2270","name":"National Institutes of Health"}],"core_research_areas":[{"id":"39441","name":"Bioengineering and Bioscience"}],"news_room_topics":[],"event_categories":[],"invited_audience":[],"affiliations":[],"classification":[],"areas_of_expertise":[],"news_and_recent_appearances":[],"phone":[],"contact":[{"value":"\u003Cp\u003ERenay San Miguel\u003C\/p\u003E\r\n\r\n\u003Cp\u003ECommunications Officer II\/Science Writer\u003C\/p\u003E\r\n\r\n\u003Cp\u003ECollege of Sciences\u003C\/p\u003E\r\n\r\n\u003Cp\u003E404-894-5209\u003C\/p\u003E\r\n","format":"limited_html"}],"email":["renay.san@cos.gatech.edu"],"slides":[],"orientation":[],"userdata":""}},"446451":{"#nid":"446451","#data":{"type":"news","title":"Georgia Tech Celebrates EBB Opening","body":[{"value":"\u003Cp\u003EIn the race to save lives, researchers know that understanding and fighting diseases requires a new method of doing things.\u003C\/p\u003E\u003Cp\u003EScientists from engineering, biology, chemistry, and computing won\u2019t discover new vaccines and medical devices \u2014 or advance what we know about diseases \u2014 by working on their own. The next biomedical breakthroughs to provide accessible health care for billions of people worldwide will come from the collaboration between different laboratories and disciplines.\u003C\/p\u003E\u003Cp\u003EThat core belief led to the creation of the Engineered Biosystems Building (EBB), the newest building at the Georgia Institute of Technology. The site opened in May and a formal dedication ceremony was held today.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003EEBB houses labs for research in chemical biology, cell and developmental biology, and systems biology. The building allows Georgia Tech to consolidate its biomedical research efforts in the prevention, diagnosis, and treatment of cancer, diabetes, heart disease, infections, and other life-threatening conditions.\u003C\/p\u003E\u003Cp\u003EPresident G.P. \u201cBud\u201d Peterson said the building symbolizes what Georgia Tech is all about \u2014 collaboration and innovation.\u003C\/p\u003E\u003Cp\u003E\u201cThe EBB will drive innovation and have an undeniable impact on biomedical science and human health,\u201d Peterson said. \u201cEBB brings together some of the world\u2019s finest researchers in a collaborative environment, and these collaborations will result in incredible breakthroughs.\u201d\u003C\/p\u003E\u003Cp\u003EThe building provides nearly 219,000 square feet of multidisciplinary research space and enhances the Institute\u2019s partnerships with Emory University Hospital and with Children\u2019s Healthcare of Atlanta.\u003C\/p\u003E\u003Cp\u003E\u201cTogether, we are changing the lives of children,\u201d said Donna Hyland, president and CEO of Children\u2019s Healthcare. \u201cThe space within this building helps bring our new Pediatric Technology Center to life and gives researchers another place to combine expertise in clinical care, research, and technology to solve problems that will help make kids better today and healthier tomorrow.\u201d\u003C\/p\u003E\u003Cp\u003EThe building is located on 10th Street, at the north end of the existing biotechnology complex. Other buildings in the complex include: the Parker H. Petit Institute for Bioengineering and Bioscience, the U.A. Whitaker Biomedical Engineering Building, the Ford Environmental Science and Technology Building, and the Molecular Science and Engineering Building.\u003C\/p\u003E\u003Cp\u003EMore than 140 faculty and nearly 1,000 graduate students from 10 different academic units work in the labs and facilities there.\u003C\/p\u003E\u003Cp\u003E\u201cEBB puts Georgia Tech at the forefront of biosciences and bioengineering research,\u201d said M.G. Finn, professor and chair of the School of Chemistry and Biochemistry.\u003C\/p\u003E\u003Cp\u003EThe building\u2019s unique design allows Georgia Tech researchers to expand their work, he said.\u003C\/p\u003E\u003Cp\u003EEBB contains \u201cresearch neighborhoods\u201d designed around a specific focus or topic. These neighborhoods bring together scientists, engineers, and researchers from different disciplines around common themes or areas of interest. They share laboratories, offices, and common spaces.\u003C\/p\u003E\u003Cp\u003EStairs alternate on various floors, encouraging people to move within the neighborhoods and throughout the building and interact with one another. Small and informal meeting areas are located near the stairwells, to further encourage researchers to talk with one another.\u003C\/p\u003E\u003Cp\u003E\u201cWe will help, influence, and support one another and bring new insights in a way that can\u2019t happen if a building is restricted to a particular department or discipline,\u201d Finn said.\u003C\/p\u003E\u003Cp\u003E\u201cUltimately we are all working to fight disease and save lives,\u201d he said. \u201cEBB is designed to foster the research to do just that.\u201d\u003C\/p\u003E\u003Cp\u003EEBB is the largest building investment in Georgia Tech history. The $113 million building was made possible because of a partnership between the Institute, the Georgia Tech Foundation, and the State of Georgia, Peterson said.\u003C\/p\u003E\u003Cp\u003EState appropriations provided $64 million for the project. Georgia Tech provided $15 million in Institute funds, and private funding raised another $34 million in commitments pledged over five years.\u003C\/p\u003E\u003Cp\u003EEBB will help drive Georgia\u2019s economy, Peterson said.\u003C\/p\u003E\u003Cp\u003E\u201cIt will foster economic development through the formation of startup enterprises, the creation of high-skilled, high-paying jobs, and the commercialization of new devices, drugs, and technologies,\u201d Peterson said.\u003C\/p\u003E","summary":null,"format":"limited_html"}],"field_subtitle":"","field_summary":[{"value":"\u003Cp\u003EResearchers in the\u0026nbsp;Engineered Biosystems Building consolidate efforts to prevent and treat cancer, diabetes, heart disease, infections, and other life-threatening conditions.\u003C\/p\u003E","format":"limited_html"}],"field_summary_sentence":[{"value":"New Engineered Biosystems Building advances biosciences, bioengineering research"}],"uid":"27918","created_gmt":"2015-09-10 14:14:47","changed_gmt":"2016-10-08 03:19:33","author":"Laura Diamond","boilerplate_text":"","field_publication":"","field_article_url":"","dateline":{"date":"2015-09-11T00:00:00-04:00","iso_date":"2015-09-11T00:00:00-04:00","tz":"America\/New_York"},"extras":[],"hg_media":{"446431":{"id":"446431","type":"image","title":"Engineered Biosystems Building view","body":null,"created":"1449256217","gmt_created":"2015-12-04 19:10:17","changed":"1475895187","gmt_changed":"2016-10-08 02:53:07","alt":"Engineered Biosystems Building view","file":{"fid":"203213","name":"ebbmove-034.jpg","image_path":"\/sites\/default\/files\/images\/ebbmove-034_0.jpg","image_full_path":"http:\/\/www.tlwarc.hg.gatech.edu\/\/sites\/default\/files\/images\/ebbmove-034_0.jpg","mime":"image\/jpeg","size":5192174,"path_740":"http:\/\/www.tlwarc.hg.gatech.edu\/sites\/default\/files\/styles\/740xx_scale\/public\/images\/ebbmove-034_0.jpg?itok=6I0oRtub"}},"446421":{"id":"446421","type":"image","title":"Engineered Biosystems Building entrance","body":null,"created":"1449256217","gmt_created":"2015-12-04 19:10:17","changed":"1475895187","gmt_changed":"2016-10-08 02:53:07","alt":"Engineered Biosystems Building entrance","file":{"fid":"203212","name":"ebbwithpeople.jpg","image_path":"\/sites\/default\/files\/images\/ebbwithpeople_0.jpg","image_full_path":"http:\/\/www.tlwarc.hg.gatech.edu\/\/sites\/default\/files\/images\/ebbwithpeople_0.jpg","mime":"image\/jpeg","size":7636976,"path_740":"http:\/\/www.tlwarc.hg.gatech.edu\/sites\/default\/files\/styles\/740xx_scale\/public\/images\/ebbwithpeople_0.jpg?itok=czJuuxTP"}},"446921":{"id":"446921","type":"image","title":"EBB ribbon cutting","body":null,"created":"1449256246","gmt_created":"2015-12-04 19:10:46","changed":"1475895187","gmt_changed":"2016-10-08 02:53:07","alt":"EBB ribbon cutting","file":{"fid":"203226","name":"ebbribboncutting.jpg","image_path":"\/sites\/default\/files\/images\/ebbribboncutting_0.jpg","image_full_path":"http:\/\/www.tlwarc.hg.gatech.edu\/\/sites\/default\/files\/images\/ebbribboncutting_0.jpg","mime":"image\/jpeg","size":3044641,"path_740":"http:\/\/www.tlwarc.hg.gatech.edu\/sites\/default\/files\/styles\/740xx_scale\/public\/images\/ebbribboncutting_0.jpg?itok=bCmY_WlC"}}},"media_ids":["446431","446421","446921"],"groups":[{"id":"1214","name":"News Room"}],"categories":[{"id":"129","name":"Institute and Campus"},{"id":"140","name":"Cancer Research"},{"id":"134","name":"Student and Faculty"},{"id":"8862","name":"Student Research"},{"id":"145","name":"Engineering"},{"id":"146","name":"Life Sciences and Biology"}],"keywords":[{"id":"146341","name":"go_genomics"}],"core_research_areas":[{"id":"39441","name":"Bioengineering and Bioscience"}],"news_room_topics":[{"id":"106361","name":"Business and Economic Development"},{"id":"71871","name":"Campus and Community"},{"id":"71891","name":"Health and Medicine"},{"id":"71881","name":"Science and Technology"}],"event_categories":[],"invited_audience":[],"affiliations":[],"classification":[],"areas_of_expertise":[],"news_and_recent_appearances":[],"phone":[],"contact":[{"value":"\u003Cp\u003ELaura Diamond\u0026nbsp;\u003Cbr \/\u003EGeorgia Tech Media Relations\u003Cbr \/\u003E404-894-6016\u003C\/p\u003E","format":"limited_html"}],"email":["laura.diamond@gatech.edu"],"slides":[],"orientation":[],"userdata":""}},"446831":{"#nid":"446831","#data":{"type":"news","title":"Small Wonders","body":[{"value":"\u003Cp class=\u0022p1\u0022\u003EGeorgia Tech scientists and engineers, in collaboration with Emory University, Children\u2019s Healthcare of Atlanta, and Marcus Autism Center, are tackling one of the biggest challenges in pediatric medicine \u2014 the lack of medical devices and technologies designed specifically for children. \u003C\/p\u003E\u003Cp class=\u0022p1\u0022\u003EMany medical devices used on children were designed for adults. And because the market for children\u2019s medical devices is small, many companies shy away from building medical technologies for children.\u003C\/p\u003E\u003Cp class=\u0022p1\u0022\u003EGeorgia Tech is helping to fill that gap in the market. From an app that allows parents to send pictures of their child\u2019s potential ear infection to a doctor, to surgical tools tailored to a child\u2019s physiology, the Institute is leading the push toward improving and saving children\u2019s lives through technology.\u003C\/p\u003E\u003Cp class=\u0022p1\u0022\u003E\u003Ca href=\u0022http:\/\/www.rh.gatech.edu\/features\/small-wonders\u0022\u003ERead more about the \u201cSmall Wonders\u201d evolving in Georgia Tech labs in this article from \u003Cem\u003EResearch Horizons\u003C\/em\u003E.\u003C\/a\u003E\u003C\/p\u003E","summary":null,"format":"limited_html"}],"field_subtitle":[{"value":"Georgia Tech and partner organizations improving the lives of children"}],"field_summary":[{"value":"\u003Cp class=\u0022p1\u0022\u003EGeorgia Tech and partner organizations improving the lives of children\u003C\/p\u003E","format":"limited_html"}],"field_summary_sentence":[{"value":"Georgia Tech and partner organizations improving the lives of children"}],"uid":"28153","created_gmt":"2015-09-11 12:00:43","changed_gmt":"2016-10-08 03:19:33","author":"Jerry Grillo","boilerplate_text":"","field_publication":"","field_article_url":"","dateline":{"date":"2015-09-11T00:00:00-04:00","iso_date":"2015-09-11T00:00:00-04:00","tz":"America\/New_York"},"extras":[],"hg_media":{"449511":{"id":"449511","type":"image","title":"Small Wonders","body":null,"created":"1449256264","gmt_created":"2015-12-04 19:11:04","changed":"1475895192","gmt_changed":"2016-10-08 02:53:12","alt":"Small Wonders","file":{"fid":"203293","name":"kidmed-thumb.jpg","image_path":"\/sites\/default\/files\/images\/kidmed-thumb_0.jpg","image_full_path":"http:\/\/www.tlwarc.hg.gatech.edu\/\/sites\/default\/files\/images\/kidmed-thumb_0.jpg","mime":"image\/jpeg","size":27987,"path_740":"http:\/\/www.tlwarc.hg.gatech.edu\/sites\/default\/files\/styles\/740xx_scale\/public\/images\/kidmed-thumb_0.jpg?itok=VifjTvOb"}},"446811":{"id":"446811","type":"image","title":"Wilbur Lam and patient","body":null,"created":"1449256246","gmt_created":"2015-12-04 19:10:46","changed":"1512765459","gmt_changed":"2017-12-08 20:37:39","alt":"","file":{"fid":"202116","name":"photo_lam_002.jpg","image_path":"\/sites\/default\/files\/images\/photo_lam_002_0.jpg","image_full_path":"http:\/\/www.tlwarc.hg.gatech.edu\/\/sites\/default\/files\/images\/photo_lam_002_0.jpg","mime":"image\/jpeg","size":435600,"path_740":"http:\/\/www.tlwarc.hg.gatech.edu\/sites\/default\/files\/styles\/740xx_scale\/public\/images\/photo_lam_002_0.jpg?itok=r7I_VDSV"}}},"media_ids":["449511","446811"],"related_links":[{"url":"http:\/\/www.rh.gatech.edu\/features\/small-wonders","title":"Small Wonders"}],"groups":[{"id":"1214","name":"News Room"}],"categories":[],"keywords":[{"id":"126201","name":"go-neural"},{"id":"141801","name":"pediatric medicine"}],"core_research_areas":[{"id":"39441","name":"Bioengineering and Bioscience"}],"news_room_topics":[{"id":"71891","name":"Health and Medicine"}],"event_categories":[],"invited_audience":[],"affiliations":[],"classification":[],"areas_of_expertise":[],"news_and_recent_appearances":[],"phone":[],"contact":[],"email":[],"slides":[],"orientation":[],"userdata":""}},"445731":{"#nid":"445731","#data":{"type":"news","title":"Moving a Lab","body":[{"value":"\u003Cp\u003ETech\u2019s latest interdisciplinary research facility, the Engineered Biosystems Building (EBB), is now open and illuminated on 10th Street. The past several months have been a flurry of activity as researchers and faculty members relocated into the new space and started breathing life into it.\u003C\/p\u003E\u003Cp\u003EBut what exactly does it take to move a lab?\u003C\/p\u003E\u003Cp\u003E\u201cYou would think that you could just get a mover and ship everything and be done, and that hasn\u2019t been the case,\u201d said Erin Kirshtein, who manages research projects and grants for Associate Professor Thomas Barker\u2019s Matrix Biology and Engineering Lab in the Wallace H. Coulter Department of Biomedical Engineering. \u201cEvery little section has its own little piece that needs multiple hands.\u201d\u003C\/p\u003E\u003Cp\u003E\u003Cstrong\u003E\u003Ca href=\u0022http:\/\/www.news.gatech.edu\/features\/moving-lab\u0022\u003ERead more about what it takes to move the labs that produce some of the world\u0027s top research.\u003C\/a\u003E\u003C\/strong\u003E\u003C\/p\u003E","summary":null,"format":"limited_html"}],"field_subtitle":"","field_summary":[{"value":"\u003Cp\u003EThe summer of 2015 was a flurry of activity for those moving into the new Engineered Biosystems Building. But what exactly does it take to move a lab?\u003C\/p\u003E","format":"limited_html"}],"field_summary_sentence":[{"value":"The summer of 2015 was a flurry of activity for those moving into the new Engineered Biosystems Building. But what exactly does it take to move a lab?"}],"uid":"27469","created_gmt":"2015-09-08 17:50:38","changed_gmt":"2016-10-08 03:19:29","author":"Kristen Bailey","boilerplate_text":"","field_publication":"","field_article_url":"","dateline":{"date":"2015-09-08T00:00:00-04:00","iso_date":"2015-09-08T00:00:00-04:00","tz":"America\/New_York"},"extras":[],"hg_media":{"445741":{"id":"445741","type":"image","title":"Moving a Lab","body":null,"created":"1449256217","gmt_created":"2015-12-04 19:10:17","changed":"1475895184","gmt_changed":"2016-10-08 02:53:04","alt":"Moving a Lab","file":{"fid":"203193","name":"moving_a_lab_icon_0.jpg","image_path":"\/sites\/default\/files\/images\/moving_a_lab_icon_0_0.jpg","image_full_path":"http:\/\/www.tlwarc.hg.gatech.edu\/\/sites\/default\/files\/images\/moving_a_lab_icon_0_0.jpg","mime":"image\/jpeg","size":99515,"path_740":"http:\/\/www.tlwarc.hg.gatech.edu\/sites\/default\/files\/styles\/740xx_scale\/public\/images\/moving_a_lab_icon_0_0.jpg?itok=gV9w8MnU"}}},"media_ids":["445741"],"related_links":[{"url":"http:\/\/www.news.gatech.edu\/features\/moving-lab","title":"Moving a Lab Feature"}],"groups":[{"id":"1292","name":"Parker H. Petit Institute for Bioengineering and Bioscience (IBB)"}],"categories":[{"id":"129","name":"Institute and Campus"}],"keywords":[{"id":"68161","name":"EBB"},{"id":"16821","name":"Engineered Biosystems Building"},{"id":"3373","name":"lab"},{"id":"365","name":"Research"},{"id":"140801","name":"web feature"}],"core_research_areas":[],"news_room_topics":[{"id":"71871","name":"Campus and Community"}],"event_categories":[],"invited_audience":[],"affiliations":[],"classification":[],"areas_of_expertise":[],"news_and_recent_appearances":[],"phone":[],"contact":[{"value":"\u003Cp\u003E\u003Ca href=\u0022mailto:kristen.bailey@comm.gatech.edu\u0022\u003EKristen Bailey\u003C\/a\u003E\u003Cbr \/\u003EInstitute Communications\u003C\/p\u003E","format":"limited_html"}],"email":[],"slides":[],"orientation":[],"userdata":""}},"398661":{"#nid":"398661","#data":{"type":"news","title":"The Mentor Experience","body":[{"value":"\u003Cp\u003EKirsten Parratt\u2019s experience as a mentor in the Project ENGAGES program is the result of a happy accident. \u003Cbr \/\u003E\u003Cbr \/\u003EParratt, in her second year as a bioengineering Ph.D. student, works as a graduate research assistant in the lab of Krishnendu Roy at the Petit Institute for Bioengineering and Bioscience. When she joined the lab, Parratt found out that part of the gig included mentoring a high school student.\u003Cbr \/\u003E\u003Cbr \/\u003E\u201cI didn\u2019t know what to expect, but when the semester rolled around I saw what Project ENGAGES is about, what a great opportunity it is for these high school students to come in and work with us,\u201d Parratt says. \u201cUnlike a normal high school program in my experience, where a student may have five hours a week in the lab, these ENGAGES students are here for 16 hours, and then all summer, too. They really have a chance to get something done, and I like that.\u201d\u003Cbr \/\u003E\u003Cbr \/\u003EIt\u2019s time well spent, in other words. Parratt is mentoring Qwantayvious Stiggers, who is nearing the end of his junior year at B.E.S.T. Academy, an all-boys high school and one of three area schools served by Project ENGAGES (for Engaging New Generations at Georgia Tech through Engineering and Science). The others are Coretta Scott King Young Women\u2019s Leadership Academy and KIPP Atlanta Collegiate, a co-ed high school.\u003Cbr \/\u003E\u003Cbr \/\u003EProject ENGAGES aims to foster a deep interest in science among students in these schools, which have student populations that are predominantly African-American, with a high percentage of kids receiving a free or subsidized lunch. The goal is to raise awareness of the students to the worlds of engineering, science and technology through real-world, hands-on experience, under the guidance of world-class researchers at the Georgia Institute of Technology. \u003Cbr \/\u003E\u003Cbr \/\u003EFounded and chaired by Bob Nerem (founding director of the Petit Institute) and Manu Plat (Petit Institute member, assistant professor in the Wallace H. Coulter Department of Biomedical Engineering) and managed by Lakeita Servance, ENGAGES is two years old. Currently there are 14 students in the biotechnology research track, administered at the Petit Institute, and nine students in the engineering research track, based at the Georgia Tech Research Institute.\u003Cbr \/\u003E\u003Cbr \/\u003EAfter mentoring in the program for the past year, Parratt is basically hooked.\u003Cbr \/\u003E\u003Cbr \/\u003E\u201cI absolutely want to continue as an ENGAGES mentor,\u201d she says. \u201cA lot of it is just seeing your student succeed. You can\u2019t look at this kind of experience as taking up more of your time. It\u2019s about making a huge difference with these young students, and clearly, they think it\u2019s the coolest thing \u2013 the chance to really see cutting edge science. When I was their age, I would have given anything for an opportunity like this.\u201d\u003Cbr \/\u003E\u003Cbr \/\u003EFor his part, Stiggers believes he is incredibly lucky \u2013 lucky to have made it through the vetting to become of Project ENGAGES; lucky to have landed in the Roy lab, where some research has focused on engineering articular cartilage. \u201cMy mother is dealing with articular cartilage problems,\u201d he says. \u201cI\u2019ve had the best of luck in getting everything I wanted here, and then to have an actual relationship between my research and my mother\u2019s health issue. I gave her a tour of the lab, and she was amazed.\u201d\u003Cbr \/\u003E\u003Cbr \/\u003ELucky, too, he says, to be paired with Parratt. \u201cWe\u2019re a great team,\u201d he says. \u201cOne of the things I like about Kirsten\u2019s style is that she doesn\u2019t treat me like I\u2019m a high school kid. At lab meetings, she\u2019ll ask my input, and so will Dr. Roy. They\u2019re serious, so I\u2019d better have something to say.\u201d\u003Cbr \/\u003E\u003Cbr \/\u003EParratt learned the rhythms of mentoring while earning her degree in Chemical and Biological Engineering at Princeton University. \u201cI had two fantastic mentors when I was an undergrad working in a lab,\u201d she says. \u201cI saw that mentoring was about helping student development. It wasn\u2019t just, \u2018here\u2019s how you do research.\u2019 It was more along the lines of, \u2018here\u2019s a class you should consider, and why,\u2019 or \u2018here\u2019s an opportunity that could help you along.\u2019\u201d\u003Cbr \/\u003E\u003Cbr \/\u003ESo she welcomed the opportunity as a grad student to be a mentor at Georgia Tech. And it seems to be catchy, one of those \u2018gifts that keep on giving\u2019 things, because Stiggers hasn\u2019t even graduated high school yet and he\u2019s already thinking long term.\u003Cbr \/\u003E\u003Cbr \/\u003E\u201cI definitely want to be a mentor some day. I want to give something back, the way Kirsten has given back to me,\u201d says Stiggers, who is looking forward to another year in the Roy lab with Parratt. \u201cWe are the dynamic duo of Project ENGAGES.\u201d\u003C\/p\u003E\u003Cp\u003E\u003Ca href=\u0022http:\/\/projectengages.gatech.edu\/become-a-mentor\u0022\u003E\u003Cstrong\u003EBecome a Project ENGAGES mentor\u003C\/strong\u003E\u003C\/a\u003E\u003C\/p\u003E\u003Cp\u003E\u003Cstrong\u003ECONTACT:\u003C\/strong\u003E\u003C\/p\u003E\u003Cp\u003E\u003Ca href=\u0022http:\/\/hg.gatech.edu\/node\/jerry.grillo@ibb.gatech.edu\u0022\u003EJerry Grillo\u003C\/a\u003E\u003Cbr \/\u003ECommunications Officer II\u003Cbr \/\u003EParker H. Petit Institute for\u003Cbr \/\u003EBioengineering and Bioscience\u003C\/p\u003E","summary":null,"format":"limited_html"}],"field_subtitle":[{"value":"\u2018Dynamic duo\u2019 link up in the lab for Project ENGAGES"}],"field_summary":[{"value":"\u003Cp\u003E\u2018Dynamic duo\u2019 link up in the lab for Project ENGAGES \u003Cbr \/\u003E\u003Cbr \/\u003E\u003C\/p\u003E","format":"limited_html"}],"field_summary_sentence":[{"value":"\u2018Dynamic duo\u2019 link up in the lab for Project ENGAGES"}],"uid":"28153","created_gmt":"2015-04-23 09:21:05","changed_gmt":"2016-10-08 03:18:03","author":"Jerry Grillo","boilerplate_text":"","field_publication":"","field_article_url":"","dateline":{"date":"2015-04-23T00:00:00-04:00","iso_date":"2015-04-23T00:00:00-04:00","tz":"America\/New_York"},"extras":[],"hg_media":{"398641":{"id":"398641","type":"image","title":"Kirsten Parratt","body":null,"created":"1449246371","gmt_created":"2015-12-04 16:26:11","changed":"1475895115","gmt_changed":"2016-10-08 02:51:55","alt":"Kirsten Parratt","file":{"fid":"75741","name":"kirsten.jpg","image_path":"\/sites\/default\/files\/images\/kirsten.jpg","image_full_path":"http:\/\/www.tlwarc.hg.gatech.edu\/\/sites\/default\/files\/images\/kirsten.jpg","mime":"image\/jpeg","size":355432,"path_740":"http:\/\/www.tlwarc.hg.gatech.edu\/sites\/default\/files\/styles\/740xx_scale\/public\/images\/kirsten.jpg?itok=BXLXnOfK"}}},"media_ids":["398641"],"groups":[{"id":"1292","name":"Parker H. Petit Institute for Bioengineering and Bioscience (IBB)"}],"categories":[{"id":"134","name":"Student and Faculty"}],"keywords":[{"id":"126581","name":"go-ProjectEngages"}],"core_research_areas":[{"id":"39441","name":"Bioengineering and Bioscience"}],"news_room_topics":[],"event_categories":[],"invited_audience":[],"affiliations":[],"classification":[],"areas_of_expertise":[],"news_and_recent_appearances":[],"phone":[],"contact":[{"value":"\u003Cp\u003E\u003Ca href=\u0022http:\/\/hg.gatech.edu\/node\/jerry.grillo@ibb.gatech.edu\u0022\u003EJerry Grillo\u003C\/a\u003E\u003Cbr \/\u003ECommunications Officer II\u003Cbr \/\u003EParker H. Petit Institute for\u003Cbr \/\u003EBioengineering and Bioscience\u003C\/p\u003E","format":"limited_html"}],"email":["jerry.grillo@ibb.gatech.edu"],"slides":[],"orientation":[],"userdata":""}},"383571":{"#nid":"383571","#data":{"type":"news","title":"2015 Suddath Symposium Hits Full Speed","body":[{"value":"\u003Cp\u003EEvery year in Atlanta, around the time winter is dragging out its transition into spring, some of the world\u2019s top researchers gather at the Parker H. Petit Institute for Bioengineering and Bioscience to present their work in a wide range of topics at the \u003Ca href=\u0022http:\/\/petitinstitute.gatech.edu\/suddath-symposium\u0022\u003ESuddath Symposium\u003C\/a\u003E. \u003Cbr \/\u003E\u003Cbr \/\u003EThis annual meeting of the minds, which opened yesterday, changes topics every year. This time it\u2019s \u201cImmunology \u0026amp; ImmunoEngineering,\u201d which is particularly timely, according to M.G. Finn, co-chair of the event with Krishnendu Roy. \u003Cbr \/\u003E\u003Cbr \/\u003E\u201cThis year\u2019s symposium brings immunologists and bioengineers\u0026nbsp;from all over the country to kick off a new initiative,\u201d says Finn, professor in and chair of the School of Chemistry and Biochemistry. \u201cGeorgia Tech, Emory, and the Georgia Research\u0026nbsp;Alliance have joined forces to help create the field of\u0026nbsp;ImmunoEngineering \u2013\u0026nbsp;the\u0026nbsp;real-time analysis and manipulation of the immune system.\u201d\u003Cbr \/\u003E\u003Cbr \/\u003EImmunoEngineering is an emerging field that builds\u0026nbsp;on\u0026nbsp;traditional immunology and the latest tools of biochemistry, molecular biology,\u0026nbsp;biophysics, and\u0026nbsp;bioinformatics. \u003Cbr \/\u003E\u003Cbr \/\u003E\u201cThere has been a real revolution in the past decade concerning our\u0026nbsp;molecular-level understanding of immunity, and Atlanta is fortunate to be the home\u0026nbsp;of many outstanding research\u0026nbsp;and clinical immunologists,\u201d says Finn. The hope, he adds, is that \u201cstudents, postdocs, and\u0026nbsp;faculty will learn from our speakers about these\u0026nbsp;newly-complementary endeavors,\u0026nbsp;and be inspired to join the effort.\u201d\u003Cbr \/\u003E\u003Cbr \/\u003E\u003Ca href=\u0022http:\/\/petitinstitute.gatech.edu\/suddath-symposium-program\u0022\u003EThis year\u2019s lineup\u003C\/a\u003E includes speakers from Emory and Georgia Tech, as usual, in addition to the University of Georgia, Massachusetts Institute of Technology (M.I.T.), University of Chicago, Stanford, the National Cancer Institute and The Scripps Research Institute. So attendees have plenty to be inspired by, including one of the event\u2019s final speakers, Julie Babensee.\u003Cbr \/\u003E\u003Cbr \/\u003E\u201cI will present on strategies to direct immune responses through key immunoregulatory cells called dendritic cells,\u201d says Babensee, whose presentation is entitled, \u201cBiomaterials for ImmunoEngineering.\u201d\u003Cbr \/\u003E\u003Cbr \/\u003ESo, there\u2019s plenty to discuss and learn today as the symposium continues. Just a sampler: Mark Davis of Stanford will present \u201cThe Nature (and Nurture) of the Human Immune System,\u201d Cheng Zhu of Emory and Georgia Tech will present, \u201cMechanical Regulation of T-Cell Biology,\u201d and Dennis Burton of The Scripps Institute will talk about HIV vaccine design. In other words, the 23rd edition of the symposium (it actually precedes the existence of the Petit Institute) is a fitting tribute to its namesake, F.L. \u201cBud\u201d Suddath.\u003Cbr \/\u003E\u003Cbr \/\u003E\u201cBud would be in awe,\u201d says Lee Suddath, whose late husband was one of the pioneers of biochemistry research and study at the Georgia Institute of Technology. \u201cI think he would be pleased. My children and I are astonished that this continues year after year, that it remains such a popular event where great science is discussed.\u201d\u003Cbr \/\u003E\u003Cbr \/\u003EAfter Suddath died suddenly in 1992, a couple of things happened to keep his memory alive. For one thing, his family, friends and colleagues established the Suddath Memorial Award, given annually to a doctoral student at Georgia Tech who demonstrates significant research achievement in biology, biochemistry or biomedical engineering. Around the same time, Suddath\u2019s fellow biochemist, Loren Williams, started the symposium. \u003Cbr \/\u003E\u003Cbr \/\u003EEach year at this time both programs merge together at the Petit Institute. The 2015 edition opened Monday with a presentation from this year\u2019s \u003Ca href=\u0022http:\/\/petitinstitute.gatech.edu\/suddath-memorial-award-0\u0022\u003ESuddath Memorial Award\u003C\/a\u003E winner, Havva Keskin, who was first author on a recently published paper, \u003Ca href=\u0022http:\/\/www.nature.com\/nature\/journal\/v515\/n7527\/abs\/nature13682.html\u0022\u003E\u201cTranscript-RNA-templated DNA recombination and repair,\u201d\u003C\/a\u003E in \u003Cem\u003ENature\u003C\/em\u003E. She kicked off the two-day celebration of science with a presentation of that research.\u003Cbr \/\u003E\u003Cbr \/\u003E\u201cThe quality of the science recognized by the Suddath Memorial Award is always high quality. It\u2019s almost like, if you don\u2019t have a paper in \u003Cem\u003ENature\u003C\/em\u003E, you don\u2019t get the Suddath Award,\u201d says Williams, who notes that the first Suddath Memorial Award winner, Mary Peek, now works in the School of Chemistry and Biochemistry at Georgia Tech (she\u2019s the Biochemistry Laboratory Program Coordinator).\u003Cbr \/\u003E\u003Cbr \/\u003EThe science changes every year, but it\u2019s always solid, it\u2019s always cutting edge. Twenty-three years ago, Loren Williams couldn\u2019t have imagined that the event he organized for a fallen friend would still be going. It wasn\u2019t part of the plan.\u003Cbr \/\u003E\u003Cbr \/\u003E\u201cBack then, we thought it would be a one-off event,\u201d says Williams, who credits former and founding Petit Institute Executive Director Bob Nerem with keeping the event alive as an annual thing. \u201cBob said, \u2018let\u2019s just keep this going.\u2019 We did, and now it has a life of its own.\u201d\u003Cbr \/\u003E\u003Cbr \/\u003E\u003C\/p\u003E\u003Cp\u003E\u003Cstrong\u003ECONTACT:\u003C\/strong\u003E\u003C\/p\u003E\u003Cp\u003E\u003Ca href=\u0022http:\/\/hg.gatech.edu\/node\/jerry.grillo@ibb.gatech.edu\u0022\u003EJerry Grillo\u003C\/a\u003E\u003Cbr \/\u003ECommunications Officer II\u003Cbr \/\u003EParker H. Petit Institute for\u003Cbr \/\u003EBioengineering and Bioscience\u003C\/p\u003E","summary":null,"format":"limited_html"}],"field_subtitle":[{"value":"Researchers put spotlight on Immunology and ImmunoEngineering"}],"field_summary":[{"value":"\u003Cp\u003EResearchers put spotlight on Immunology and ImmunoEngineering\u003Cbr \/\u003E\u003Cbr \/\u003E\u003C\/p\u003E","format":"limited_html"}],"field_summary_sentence":[{"value":"Researchers put spotlight on Immunology and ImmunoEngineering"}],"uid":"28153","created_gmt":"2015-03-03 09:47:25","changed_gmt":"2016-10-08 03:02:51","author":"Jerry Grillo","boilerplate_text":"","field_publication":"","field_article_url":"","dateline":{"date":"2015-03-03T00:00:00-05:00","iso_date":"2015-03-03T00:00:00-05:00","tz":"America\/New_York"},"extras":[],"hg_media":{"383561":{"id":"383561","type":"image","title":"Havva Keskin, Lee Suddath","body":null,"created":"1449246246","gmt_created":"2015-12-04 16:24:06","changed":"1475894395","gmt_changed":"2016-10-08 02:39:55","alt":"Havva Keskin, Lee Suddath","file":{"fid":"75339","name":"havva_and_lee.jpg","image_path":"\/sites\/default\/files\/images\/havva_and_lee.jpg","image_full_path":"http:\/\/www.tlwarc.hg.gatech.edu\/\/sites\/default\/files\/images\/havva_and_lee.jpg","mime":"image\/jpeg","size":3181093,"path_740":"http:\/\/www.tlwarc.hg.gatech.edu\/sites\/default\/files\/styles\/740xx_scale\/public\/images\/havva_and_lee.jpg?itok=gPmm0Hgl"}}},"media_ids":["383561"],"groups":[{"id":"1254","name":"Wallace H. Coulter Dept. of Biomedical Engineering"}],"categories":[],"keywords":[{"id":"6500","name":"Petit Institute"},{"id":"169343","name":"suddath"}],"core_research_areas":[{"id":"39441","name":"Bioengineering and Bioscience"}],"news_room_topics":[],"event_categories":[],"invited_audience":[],"affiliations":[],"classification":[],"areas_of_expertise":[],"news_and_recent_appearances":[],"phone":[],"contact":[{"value":"\u003Cp\u003E\u003Ca href=\u0022http:\/\/hg.gatech.edu\/node\/jerry.grillo@ibb.gatech.edu\u0022\u003EJerry Grillo\u003C\/a\u003E\u003Cbr \/\u003ECommunications Officer II\u003Cbr \/\u003EParker H. Petit Institute for\u003Cbr \/\u003EBioengineering and Bioscience\u003C\/p\u003E","format":"limited_html"}],"email":["jerry.grillo@ibb.gatech.edu"],"slides":[],"orientation":[],"userdata":""}},"381951":{"#nid":"381951","#data":{"type":"news","title":"Developing Better Options","body":[{"value":"\u003Cp\u003EThe reality of war is as grim today as it ever was:\u0026nbsp; soldiers put themselves in harm\u2019s way with predictable results. What\u2019s changed is, the predictions are better than they used to be. So thanks to advances in emergency, in-theater medicine, the U.S. Armed Forces\u2019 wounded-to-fatality ratio went from 2:1 in World War II to 8:1 in the Iraq\/Afghanistan conflicts, according to the Philanthropy Roundtable publication, \u003Ca href=\u0022http:\/\/www.philanthropyroundtable.org\/guidebook\/serving_those_who_served_a_wise_givers_guide\/veterans\u0022\u003E\u003Cem\u003EServing Those Who Served.\u003C\/em\u003E\u003C\/a\u003E \u0026nbsp;\u003Cbr \/\u003E\u003Cbr \/\u003EThe inevitable result is that a large number of service members and veterans are living with challenging injuries and disabilities. It\u2019s a reality that underscores the timely importance of the research being done right now at the \u003Ca href=\u0022http:\/\/www.gatech.edu\/\u0022\u003EGeorgia Institute of Technology\u003C\/a\u003E and its partner institutions, who came together recently for the first Military and Veterans Healthcare Technologies Symposium.\u003C\/p\u003E\u003Cp\u003EAbout 90 scientists, engineers, students, and representatives from the Department of Defense gathered recently at the \u003Ca href=\u0022http:\/\/petitinstitute.gatech.edu\/\u0022\u003EParker H. Petit Institute for Bioengineering and Bioscience\u003C\/a\u003E, where they shared leading-edge research that addresses the health challenges facing military personnel. Because, while the reality of war may be as grim as ever, soldiers are surviving injuries in greater numbers, which demands better therapeutic and rehabilitative options.\u003C\/p\u003E\u003Cp\u003E\u201cThe symposium really exceeded my expectations in every way,\u201d says Robert Guldberg, executive director of the Petit Institute and professor in the George W. Woodruff School of Mechanical Engineering. \u201cThe purpose was to highlight military health-related research at Georgia Tech, \u003Ca href=\u0022http:\/\/www.emory.edu\/home\/index.html\u0022\u003EEmory\u003C\/a\u003E, and the \u003Ca href=\u0022http:\/\/uga.edu\/\u0022\u003EUniversity of Georgia\u003C\/a\u003E (UGA). We have established very strong collaborations among the three institutions in areas like regenerative medicine, neuro-engineering, and prosthetics and orthotics.\u201d\u003C\/p\u003E\u003Cp\u003E\u003Cbr \/\u003EIt took a collaborative effort on all fronts to produce the symposium. The event was co-sponsored by the Center for Advanced Bioengineering and Soldier Survivability (CABSS) at Georgia Tech, a U.S. Army funded research grant coming to a close this year, and the \u003Ca href=\u0022http:\/\/regenerativeengineeringandmedicine.com\/\u0022\u003ECenter for Regenerative Engineering and Medicine\u003C\/a\u003E (REM).\u0026nbsp; REM is a collaborative center led by co-directors Steve Stice (UGA), Ned Waller (Emory), and Johnna Temenoff (Georgia Tech).\u0026nbsp;The symposium was organized by Tom Barker, Petit Faculty Fellow and associate professor in the \u003Ca href=\u0022https:\/\/bme.gatech.edu\/\u0022\u003EWallace H. Coulter Department of Biomedical Engineering\u003C\/a\u003E (BME), and Martha Willis, program manager in the Woodruff School.\u003C\/p\u003E\u003Cp\u003EResearch in technologies addressing a wide range of clinical challenges in the military and veteran\u2019s population were presented throughout the day, and a poster session to highlight additional projects and research efforts encouraged symposium participants to network and look for areas of common interests and focus. \u0026nbsp;\u003C\/p\u003E\u003Cp\u003ETopic Highlights:\u003C\/p\u003E\u003Cp\u003EPost traumatic osteoarthritis (OA), a debilitating and extremely painful condition characterized by gradual but progressive degradation of the cartilage surrounding the joints is often the result of battlefield injuries and it plagues wounded soldiers and veterans at rates higher than that of the general population. Effective pain relief for OA is limited and, remarkably, no disease modifying OA drugs are currently approved. Researchers at Georgia Tech are developing therapies and strategies for intra-articular delivery of micronized human amnion membrane that have shown promise in preventing the development of osteoarthritis following knee trauma in animal studies, and have gone on to show that they can regenerate regions of degraded cartilage in already arthritic joints.\u003C\/p\u003E\u003Cp\u003EImmunoEngineering, or the application of engineering tools and principles to quantitatively study the immune system in health and disease, allows researchers to develop new and improved therapies by precisely controlling and modulating a patient\u2019s immune response. Researchers at Georgia Tech\u2019s \u003Ca href=\u0022http:\/\/www.immunoengineering.gatech.edu\/\u0022\u003ECenter for ImmunoEngineering\u003C\/a\u003E discussed \u201cImmuno-Engineering Soldier Health: From Sepsis and Trauma to Rehabilitation and Regeneration.\u201d\u0026nbsp; Krishnendu Roy, the center director described his center as a collaboration of engineers, chemists, physicist, computational scientists, and immunologists, focused on a broad range of diseases.\u0026nbsp; He emphasized that correcting the long term immune-imbalance that causes chronic inflammation and suppresses many of the body\u2019s natural healing mechanisms is critical for the success of any regenerative and rehabilitative therapies in our wounded warriors.\u003Cbr \/\u003E\u003Cbr \/\u003EOther researchers at Georgia Tech and the Atlanta Veterans Affairs Medical Center outlined work conducted in their laboratories and facilities in regenerative engineering strategies for tendon overuse, extremity trauma and complex, multi-tissue injuries that simultaneously effect bone, muscle, vasculature and neural anatomy.\u0026nbsp; Existing injury models tend to address individual components, but composite defect models and methods are bringing these technologies to the point of translation to human trials and actual clinical application.\u0026nbsp; At UGA, researchers highlighted regenerative medicine efforts in bone fracture healing and nerve repair following traumatic brain injury. \u0026nbsp;\u003Cbr \/\u003E\u003Cbr \/\u003ENovel engineering approaches to hemostasis, scar formation and contracture as well as infection fighting materials that could be brought to bear on battlefield injuries were discussed, and researchers from Emory addressed neuromuscular control as well as some of the clinical complications associated with extremity amputation.\u0026nbsp; Reminding us of the long-term reality of our military veterans living with amputations, one of the final presentations addressed the challenges of improving the technology behind prosthetic sockets, as researchers attempt to find solutions that improve comfort and function.\u003Cbr \/\u003E\u003Cbr \/\u003EThe symposium wrapped up with a presentation by one of the invited military guests, Brian Pfister from the U.S. Army\u2019s Clinical and Rehabilitative Medicine Research Program (CRMR), entitled \u201cDoD Priorities and Opportunities for Regenerative and Rehabilitative Technologies.\u201d\u0026nbsp; Following his presentation, a long line of symposium participants waited to pick Pfister\u2019s brain. This was expected and one of the main reasons for the symposium, which organizers saw as a chance to become better acquainted with Department of Defense goals and funding priorities. They also saw it as a community-building event where researchers could explore new synergies and begin developing multi-investigator grant opportunities.\u003C\/p\u003E\u003Cp\u003E\u201cAt the end of the day, I felt incredibly energized by the research progress presented and the potential these technologies have to impact critical health issues experienced by our military personnel in very significant ways,\u201d says Guldberg. \u201cOur faculty and their students are clearly on the front lines of the latest advancements, whether we are talking about new approaches for treating acute problems like extremity trauma, bleeding, or infections, or the longer-term challenges associated with traumatic brain injury, post-traumatic osteoarthritis, or optimizing the functional mobility of amputees.\u201d\u003C\/p\u003E\u003Cp\u003EIn addition to Pfister, military guests at the symposium included Eva Lai of the Congressionally Directed Medical Research Programs (CDMRP), Bob Christy of the Army Institute of Surgical Research (AISR), and Susan Taylor and Mike Leggier of the Armed Forces Institute for Regenerative Medicine (AFIRM). Their presence, the nature of the research that was on display (including the stark images of soldiers\u2019 injuries), and Pfister\u2019s explanation of priority areas (extremity regeneration in the areas of muscle, nerve, and vascular) emphasized the ultimate purpose of the symposium, and the challenges facing researchers in this field. \u003Cbr \/\u003E\u003Cbr \/\u003E\u201cWe have to keep in mind that this is not research as usual, but really focused on developing and translating healthcare technologies that help put back together our military personnel injured during service to our country,\u201d Guldberg says. \u201cThis symposium served as a small but important step in that direction by bringing together like-minded members of our community and connecting with key program leaders at the Department of Defense.\u201d \u003Cbr \/\u003E\u003Cbr \/\u003E\u003C\/p\u003E\u003Cp\u003E\u003Cstrong\u003EContact:\u003C\/strong\u003E\u003C\/p\u003E\u003Cp\u003E\u003Ca href=\u0022http:\/\/hg.gatech.edu\/node\/jerry.grillo@ibb.gatech.edu\u0022\u003EJerry Grillo\u003C\/a\u003E\u003Cbr \/\u003ECommunications Officer II\u003Cbr \/\u003EParker H. Petit Institute for\u003Cbr \/\u003EBioengineering and Bioscience\u003C\/p\u003E","summary":null,"format":"limited_html"}],"field_subtitle":[{"value":"Military Healthcare Technology Symposium showcases cutting edge research"}],"field_summary":[{"value":"\u003Cp\u003EMilitary Healthcare Technology Symposium showcases cutting edge research\u003Cbr \/\u003E\u003Cbr \/\u003E\u003C\/p\u003E","format":"limited_html"}],"field_summary_sentence":[{"value":"Military Healthcare Technology Symposium showcases cutting edge research"}],"uid":"28153","created_gmt":"2015-02-24 13:58:45","changed_gmt":"2016-10-08 03:02:34","author":"Jerry Grillo","boilerplate_text":"","field_publication":"","field_article_url":"","dateline":{"date":"2015-02-24T00:00:00-05:00","iso_date":"2015-02-24T00:00:00-05:00","tz":"America\/New_York"},"extras":[],"hg_media":{"381931":{"id":"381931","type":"image","title":"Guldberg and Lam","body":null,"created":"1449246231","gmt_created":"2015-12-04 16:23:51","changed":"1475894382","gmt_changed":"2016-10-08 02:39:42","alt":"Guldberg and Lam","file":{"fid":"75294","name":"bob_and_wilbur.jpg","image_path":"\/sites\/default\/files\/images\/bob_and_wilbur.jpg","image_full_path":"http:\/\/www.tlwarc.hg.gatech.edu\/\/sites\/default\/files\/images\/bob_and_wilbur.jpg","mime":"image\/jpeg","size":1256448,"path_740":"http:\/\/www.tlwarc.hg.gatech.edu\/sites\/default\/files\/styles\/740xx_scale\/public\/images\/bob_and_wilbur.jpg?itok=XMO2hdDC"}}},"media_ids":["381931"],"groups":[{"id":"1254","name":"Wallace H. Coulter Dept. of Biomedical Engineering"}],"categories":[],"keywords":[{"id":"119521","name":"military healthcare technology"},{"id":"119531","name":"veterans medicine"}],"core_research_areas":[{"id":"39441","name":"Bioengineering and Bioscience"}],"news_room_topics":[],"event_categories":[],"invited_audience":[],"affiliations":[],"classification":[],"areas_of_expertise":[],"news_and_recent_appearances":[],"phone":[],"contact":[{"value":"\u003Cp\u003E\u003Ca href=\u0022http:\/\/hg.gatech.edu\/node\/jerry.grillo@ibb.gatech.edu\u0022\u003EJerry Grillo\u003C\/a\u003E\u003Cbr \/\u003ECommunications Officer II\u003Cbr \/\u003EParker H. Petit Institute for\u003Cbr \/\u003EBioengineering and Bioscience\u003C\/p\u003E","format":"limited_html"}],"email":["jerry.grillo@ibb.gatech.edu"],"slides":[],"orientation":[],"userdata":""}},"350981":{"#nid":"350981","#data":{"type":"news","title":"The Buzz on Bioscience","body":[{"value":"\u003Cp class=\u0022intro-text\u0022\u003EBiomedical engineering at Georgia Tech has risen from a handful of projects to national prominence in just two decades. Today, more than half of all incoming freshman pursue a degree in biomedical engineering, biochemistry, or biology. These students want to both understand living systems and make things that improve people\u2019s lives.\u003C\/p\u003E\u003Cp\u003ENow, more than ever, those opportunities are plentiful in biosciences at Georgia Tech, where researchers are creating medical devices for children, understanding how diseases occur, improving vaccines, and building better biomaterials for drug delivery. Georgia Tech\u2019s unique blend of engineering, biology, chemistry, and computing \u2014 along with partnerships with world-class medical facilities in Atlanta, such as Emory University and Children\u2019s Healthcare of Atlanta \u2014 has transformed the Institute\u2019s campus into a magnet for bio-minded scientists.\u003C\/p\u003E\u003Cp\u003E\u201cWhat we bring to the table is a new perspective in the biological sciences that is data driven, that is quantitative, that focuses on devices and techniques and on being unafraid to ask fundamental questions,\u201d said Ravi Bellamkonda, the chair and professor of the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University. \u201cIt\u2019s a different approach to biology as an engineer.\u201d\u003C\/p\u003E\u003Cp\u003EThe rise of biomedical engineering at Georgia Tech has created a ripple effect across the biosciences on campus. Biologists studying genetics, ecology, and personalized medicine are collaborating with engineers to solve challenging medical problems. The bio quad, home to the Parker H. Petit Institute for Bioengineering and Bioscience (IBB); the U.A. Whitaker Biomedical Engineering Building; the Ford Environmental Science and Technology (ES\u0026amp;T) Building; and the Molecular Science and Engineering (M) Building, already forms a hub of interdisciplinary research. Soon, other collaboration-oriented buildings will be added, solidifying the Institute\u2019s commitment to developing its bioscience portfolio, which touches everything from mechanical engineering, to electrical engineering, to materials science and engineering.\u003C\/p\u003E\u003Cp\u003EBioscience the Georgia Tech way has attracted high-profile faculty, such as M.G. Finn, pioneer of click chemistry and rumored Nobel Prize candidate. Also flocking to campus are fresh young minds, such as Susan N. Thomas, an assistant professor in the new field of immunoengineering. These researchers and others, who might not have come to Georgia Tech even 10 years ago, say that the Institute is already making a dent in some of the world\u2019s biggest medical challenges, and is poised to do more. Nascent fields of research, such as immunoengineering, systems biology, pediatric bioengineering, chemical biology, and biomanufacturing, are emerging strengths on campus, positioning Georgia Tech to help define what these fields become. Georgia Tech is already recognized as a leader in regenerative medicine, cardiovascular engineering, neuroengineering, and mechanobiology.\u003C\/p\u003E\u003Cp\u003E\u201cConsidering what had been done in the past 10 years, I thought the next 10 years at Georgia Tech would be pretty exciting,\u201d said Finn, the interim chair and professor of the School of Chemistry and Biochemistry. \u201cVery few places in the world \u2014 if anywhere \u2014 will embed fundamental science in with applications science and technology better than we do here.\u201d\u003C\/p\u003E\u003Cp\u003ERead more\u0026nbsp;of this article from Georgia Tech\u0027s\u0026nbsp;\u003Ca href=\u0022http:\/\/www.rh.gatech.edu\/features\/buzz-bioscience\u0022\u003E\u003Cem\u003EResearch Horizons\u003C\/em\u003E\u0026nbsp;magazine\u003C\/a\u003E.\u003C\/p\u003E","summary":null,"format":"limited_html"}],"field_subtitle":"","field_summary":"","field_summary_sentence":[{"value":"The biosciences are big at Georgia Tech. Researchers discuss what\u2019s happening and how they see the future."}],"uid":"27902","created_gmt":"2014-12-02 12:30:07","changed_gmt":"2016-10-08 03:17:37","author":"Brett Israel","boilerplate_text":"","field_publication":"","field_article_url":"","dateline":{"date":"2014-12-02T00:00:00-05:00","iso_date":"2014-12-02T00:00:00-05:00","tz":"America\/New_York"},"extras":[],"hg_media":{"351001":{"id":"351001","type":"image","title":"Bioscience faces","body":null,"created":"1449245714","gmt_created":"2015-12-04 16:15:14","changed":"1475895078","gmt_changed":"2016-10-08 02:51:18","alt":"Bioscience faces","file":{"fid":"201961","name":"bioscience_teaser.jpg","image_path":"\/sites\/default\/files\/images\/bioscience_teaser.jpg","image_full_path":"http:\/\/www.tlwarc.hg.gatech.edu\/\/sites\/default\/files\/images\/bioscience_teaser.jpg","mime":"image\/jpeg","size":62236,"path_740":"http:\/\/www.tlwarc.hg.gatech.edu\/sites\/default\/files\/styles\/740xx_scale\/public\/images\/bioscience_teaser.jpg?itok=hGREcob5"}}},"media_ids":["351001"],"groups":[{"id":"1214","name":"News Room"}],"categories":[{"id":"140","name":"Cancer Research"},{"id":"146","name":"Life Sciences and Biology"}],"keywords":[{"id":"249","name":"Biomedical Engineering"},{"id":"762","name":"Bioscience"},{"id":"1503","name":"Biotechnology"},{"id":"93761","name":"Krish Roy"},{"id":"10832","name":"Manu Platt"},{"id":"5084","name":"Melissa Kemp"},{"id":"111331","name":"mg finn"},{"id":"2471","name":"Ravi Bellamkonda"},{"id":"169542","name":"Susan Thomas"}],"core_research_areas":[{"id":"39441","name":"Bioengineering and Bioscience"}],"news_room_topics":[{"id":"71891","name":"Health and Medicine"},{"id":"71881","name":"Science and Technology"}],"event_categories":[],"invited_audience":[],"affiliations":[],"classification":[],"areas_of_expertise":[],"news_and_recent_appearances":[],"phone":[],"contact":[{"value":"\u003Cp\u003EBrett Israel\u003C\/p\u003E\u003Cp\u003E404-491-6792\u003C\/p\u003E\u003Cp\u003E\u003Ca href=\u0022http:\/\/www.twitter.com\/btiatl\u0022\u003E@btiatl\u003C\/a\u003E\u003C\/p\u003E","format":"limited_html"}],"email":["brett.israel@comm.gatech.edu"],"slides":[],"orientation":[],"userdata":""}},"299151":{"#nid":"299151","#data":{"type":"news","title":"Four Georgia Tech Researchers Recognized as Top 20 Medical Researchers in the State","body":[{"value":"\u003Cp\u003E\u003Cstrong\u003EFour scientists at the Georgia Institute of Technology are among the top medical researchers in Georgia, according to the Atlanta Business Chronicle.\u003C\/strong\u003E\u003Cbr \/\u003E\u003Cbr \/\u003EFour scientists at the Georgia Institute of Technology are among the top medical researchers in Georgia, according to the \u003Cem\u003EAtlanta Business Chronicle\u0026nbsp;\u003C\/em\u003Ein a recent cover story (May 16-22 edition). But to hear them tell it, the number could easily be much higher.\u003C\/p\u003E\u003Cp\u003E\u201cIt\u2019s a nice honor, to be recognized like this, but all of us are engaged in a number of collaborative efforts, so any successes we achieve individually represent the efforts of a broad community of our collaborators and colleagues,\u201d says Todd McDevitt, Carol Ann and David D. Flanagan professor in the Wallace H. Coulter Department of Biomedical Engineering and also director of the Stem Cell Engineering Center. \u201cCollectively, we\u2019re a lot stronger than the individual pieces alone.\u201d\u003C\/p\u003E\u003Cp\u003EMcDevitt, along with Ravi Bellamkonda, Ross Ethier and Krishnendu Roy are among the 20 scientists featured in the article by Ellie Hensley, who writes, \u201cRespected research universities like Georgia Tech and Emory University draw top talent, and a high level of collaborations between institutions like these creates a unique environment for scientists in the state.\u201d\u003C\/p\u003E\u003Cp\u003EIndeed, partnerships with other institutions \u2013 like the one between Georgia Tech and Emory resulting in the Wallace H. Coulter Department of Biomedical Engineering \u2013 are a big reason these scientists happen to be here.\u003C\/p\u003E\u003Cp\u003E\u201cThat was very important to me. The collaborative effort is definitely something that attracted me to Georgia Tech \u2013 that, and also the opportunity to work with highly talented people who work in similar research areas,\u201d says Roy, Carol Ann and David D. Flanagan Professor and Director of the Center for Immunoengineering at Georgia Tech, who came here from the University of Texas at Austin last summer.\u003C\/p\u003E\u003Cp\u003ERegarding the Georgia Tech-Emory collaboration, Ethier adds, \u201cThe idea of a partnership between public and private universities is certainly unusual, and a testament to people having vision and foresight.\u201d\u0026nbsp;\u003C\/p\u003E\u003Cp\u003EEthier, the Georgia Research Alliance (GRA) Lawrence L. Gellerstedt, Jr. Eminent Scholar in Bioengineering, researches the biomechanics of cells and whole organs, targetting, among other things, glaucoma and new ways to treat the condition, which is the second most common cause of blindness. But it takes a collaborative, interdisciplinary approach, and enthusiastic support and leadership from a variety of sources, to make groundbreaking discoveries, and all of that is in place here, enough of it to have lured Ethier from the UK to Atlanta.\u003C\/p\u003E\u003Cp\u003E\u201cThe GRA provided me with the infrastructure to kick-start my research here, and that was really important,\u201d says Ethier. \u201cAnd there\u2019s a can-do attitude here that\u2019s so refreshing. You\u2019re talking to folks, you ask a question and they tend to say, \u2018yeah, we can figure out a way to make that happen.\u2019\u201d\u003C\/p\u003E\u003Cp\u003EThat willingness to make things happen \u2013 and also to take risks \u2013 is one of the human (and institutional) elements that appeals most to Bellamkonda, who chairs the Wallace H. Coulter Department of Biomedical Engineering, and researches neural tissue engineering and cancer and is working to develop targeted drug delivery for brain tumor therapy.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003E\u201cIn my mind, we have a can-do, fearless attitude in medical research that perhaps comes from the influence of engineering thought in medicine,\u201d he says. \u201cIn my personal case, I\u0027ve realized somewhere along the way that research is not about building a career \u2013 its about making progress and having an impact. Kids and older patients who might benefit from our research don\u0027t have the luxury of time \u2013 they need the advances we are working on today.\u0026nbsp;And for this reason, it is worth taking on higher risk, high reward projects to complement more incremental research.\u0026nbsp;These two elements - not being afraid of failure, and the need to make progress at a different pace than the field as a whole is moving, lead to breakthroughs in my mind.\u0026nbsp;And my experience is completely consistent with this.\u201d\u003C\/p\u003E\u003Cp\u003EAtlanta and Georgia, while not yet in the same league with longtime bio centers like Boston or San Francisco, is nonetheless a powerful and growing hub of activity. The state is 12\u003Csup\u003Eth\u003C\/sup\u003E in research funding, and Atlanta is fifth in research expenditures, according to the article in the \u003Cem\u003EAtlanta Business Chronicle\u003C\/em\u003E.\u003C\/p\u003E\u003Cp\u003ESo, these four scientists, and their colleagues at Georgia Tech and across the state, are the architects of a new age in medical research. And Georgia\u2019s institutions and researchers already are setting the pace in some fields. The next big step, of course, is translating this research into commercial use, and part of that involves the creation or development of new jobs to transform the growing health industry.\u003C\/p\u003E\u003Cp\u003ETake, for example, the NSF-funded Integrative Graduate Education and Research Traineeship (IGERT) program in stem cell biomanufacturing. Awarded to Georgia Tech in 2010, the program is designed to educate and train the first generation of Ph.D. students in the translation and commercialization of stem cell technologies for diagnostic and therapeutic applications.\u003C\/p\u003E\u003Cp\u003E\u201cWe\u2019re at an exciting point in Georgia where new initiatives are originating and ready to take off,\u201d McDevitt says. \u201cWe\u2019re not a traditional hub, where they\u2019ve got an established culture. We\u2019re still creating ours, and being at the forefront of leading new fields is exhilarating. We can have a significant impact in defining what the goals and objectives are going to be, and that will really inform industry.\u201d\u003C\/p\u003E","summary":null,"format":"limited_html"}],"field_subtitle":[{"value":"Four scientists at the Georgia Institute of Technology are among the top medical researchers in Georgia, according to the Atlanta Business Chronicle."}],"field_summary":[{"value":"\u003Cp\u003EFour scientists at the Georgia Institute of Technology are among the top medical researchers in Georgia, according to the\u0026nbsp;\u003Cem\u003EAtlanta Business Chronicle\u003C\/em\u003E\u0026nbsp;in a recent cover story (May 16-22 edition). But to hear them tell it, the number could easily be much higher.\u003C\/p\u003E","format":"limited_html"}],"field_summary_sentence":[{"value":"Four scientists at the Georgia Institute of Technology are among the top medical researchers in Georgia, according to the Atlanta Business Chronicle."}],"uid":"27224","created_gmt":"2014-05-21 17:55:59","changed_gmt":"2016-10-08 03:16:29","author":"Megan McDevitt","boilerplate_text":"","field_publication":"","field_article_url":"","dateline":{"date":"2014-05-21T00:00:00-04:00","iso_date":"2014-05-21T00:00:00-04:00","tz":"America\/New_York"},"extras":[],"hg_media":{"299161":{"id":"299161","type":"image","title":"Four Researchers","body":null,"created":"1449244552","gmt_created":"2015-12-04 15:55:52","changed":"1475895000","gmt_changed":"2016-10-08 02:50:00","alt":"Four Researchers","file":{"fid":"199487","name":"fourresearchers2.jpg","image_path":"\/sites\/default\/files\/images\/fourresearchers2_0.jpg","image_full_path":"http:\/\/www.tlwarc.hg.gatech.edu\/\/sites\/default\/files\/images\/fourresearchers2_0.jpg","mime":"image\/jpeg","size":1455809,"path_740":"http:\/\/www.tlwarc.hg.gatech.edu\/sites\/default\/files\/styles\/740xx_scale\/public\/images\/fourresearchers2_0.jpg?itok=thG-TcLX"}}},"media_ids":["299161"],"related_links":[{"url":"http:\/\/mcdevitt.gatech.edu\/","title":"McDevitt Research Lab"},{"url":"http:\/\/ethier.gatech.edu\/","title":"Ethier lab"},{"url":"http:\/\/roylab.gatech.edu\/roy\/index.html","title":"Roy lab website"},{"url":"http:\/\/www.ravi.gatech.edu\/","title":"Bellamkonda lab website"},{"url":"http:\/\/www.ibb.gatech.edu\/","title":"Petit Institute for Bioengineering and Bioscience"}],"groups":[{"id":"1292","name":"Parker H. Petit Institute for Bioengineering and Bioscience (IBB)"}],"categories":[],"keywords":[{"id":"12515","name":"College of Engineering; Wallace H. Coulter Department of Biomedical Engineering; Emory; Children\u0027s Healthcare of Atlanta; pediatric nanomedicine;  Gang Bao"},{"id":"93761","name":"Krish Roy"},{"id":"2471","name":"Ravi Bellamkonda"},{"id":"41331","name":"Ross Ethier"},{"id":"760","name":"Todd McDevitt"}],"core_research_areas":[{"id":"39441","name":"Bioengineering and Bioscience"}],"news_room_topics":[],"event_categories":[],"invited_audience":[],"affiliations":[],"classification":[],"areas_of_expertise":[],"news_and_recent_appearances":[],"phone":[],"contact":[{"value":"\u003Cp\u003E\u003Ca href=\u0022mailto:jerry.grillo@ibb.gatech.edu\u0022\u003EJerry Grillo\u003C\/a\u003E\u003Cbr \/\u003ECommunications Officer II\u003Cbr \/\u003EParker H. Petit Institute\u003Cbr \/\u003Efor Bioengineering and Bioscience\u003Cbr \/\u003E\u003Cbr \/\u003E\u003C\/p\u003E","format":"limited_html"}],"email":["jerry.grillo@ibb.gatech.edu"],"slides":[],"orientation":[],"userdata":""}},"295011":{"#nid":"295011","#data":{"type":"news","title":"Immunoengineering and Convergence Science","body":[{"value":"\u003Cp\u003EMy first significant exposure to Immunology was in my first year of PhD at Johns Hopkins. In those days there were only 8-10 students admitted to the BME doctoral program at Hopkins and everyone had to go through the basic science curriculum in the medical school. So, that first year I did not take any engineering or math classes; rather, with my fellow medical students immersed in dissecting cadaver, taking anatomy, physiology, neuroscience and developmental biology. But it was immunology that fascinated me. I came from an electrical engineering, control systems background, and the intricate feedback control of the human immune system, its redundancies and its stability in the midst of chaos, simply blew me away. Ever since, I have been amazed and excited by the idea that engineers can quantitatively study the immune system to understand its behavior in health and precisely modulate it in diseases to help patients. \u003Cbr \/\u003E\u003Cbr \/\u003E Fast forward two decades and we are now experiencing a revolution in how we think of human diseases and how we approach to solve them. I don\u2019t think I know of any disease where the immune system is not intricately involved. From a simple fever and cough to cancer and HIV, from a rash or a cut to autoimmune and cardiovascular diseases; immunology plays a central role in keeping us healthy and manifesting our diseases. Our fundamental knowledge of biology and how cells, organs and systems physiology work together have increased exponentially over the past two decades and with that has come much appreciation of immunological balance and the potential of modulating ones immune system to treat devastating diseases like cancer, multiple sclerosis, diabetes, lupus, HIV and others. \u003Cbr \/\u003E\u003Cbr \/\u003E So how do engineers fit into this picture? The involvement of engineers and engineering sciences (i.e. the application of physics, chemistry and math) is not new to immunology. Material scientists, chemists, pharmaceutical researchers as well as chemical and bioengineers have worked on implant pathology, vaccine delivery and drug delivery for decades. What has changed now is the broad acceptance that engineers are critical for understanding fundamental immunology, modeling diseases and disease outcomes, developing new tools for high throughput assays and analysis, providing new strategies for immune-modulation, and improving our understanding of the immune system through systems immunology and synthetic biology.\u003Cbr \/\u003E\u003Cbr \/\u003E Immunologists and biologists have been the first to embrace the idea of partnering with engineers, develop new quantitative tools to study and solve diseases, and to understand the fundamental physics and chemistry of the immune system. The landscape of how we look at a disease process and how we benchmark normal homeostasis has clearly shifted to an engineering-driven approach. Immunologists, biologists and clinicians have converged with physicists, chemists, computational scientist as well as chemical, electrical, mechanical and bioengineers to launch an all-out attack against devastating diseases using the immune system as their fundamental weapon. \u003Cbr \/\u003E\u003Cbr \/\u003E It is in this backdrop that this past fall Georgia Tech launched what could be the first ever \u003Ca href=\u0022http:\/\/www.immunoengineering.gatech.edu\u0022\u003ECenter for Immunoengineering\u003C\/a\u003E in the nation. Given GT\u0027s strength in biosciences and bioengineering under the convergence of the Parker H. Petit Institute of Bioengineering \u0026amp; Bioscience, along with its partnership with the world renowned immunology expertise at Emory, this was an obvious choice, but certainly a visionary one. More than 30 faculty across 7 schools are part of this unique endeavor that, for the first time provides a concerted effort in engineering our immune system and solving some of the most critical problems in human health: from cancer to HIV, from diabetes to transplant rejection, from regenerative medicine to multiple sclerosis. Earlier this year, powered by a strong support from the Georgia Research Alliance (GRA), Georgia Tech and Emory launched the broader \u003Ca href=\u0022http:\/\/www.immunoengineering-georgia.org\u0022\u003EGeorgia Immunoengineering Consortium\u003C\/a\u003E (GIEC). With over 60 faculty members from both universities and incredible support from the GRA, Georgia Tech and Emory administrations, the GIEC is poised to become the world leader in creating breakthrough engineering tools, methods and solutions for understanding and modulating the immune system and developing new solutions for personalized and predictive health-care. We envision that in the near future when a patient walks into their office, doctors would routinely and rapidly assess the comprehensive \u201cimmune-status\u201d of a patient just like they do a blood test or an MRI, take that assessment data and quantitatively predict immune function and disease state using modeling and data-driven analysis and finally use materials-driven tools and engineering approaches to enhance and modulate the patient\u2019s immune system and eliminate or alleviate their disease. \u003Cbr \/\u003E\u003Cbr \/\u003E In the midst of this exciting research environment, it is critical that we develop sound policies to train our students and fellows in this emerging \u201cconvergence science\u201d area of Immunoengineering. As I look back to my own training decades ago, I realize the fundamental principle remains the same. Trainees must be versed at both languages; they must fundamentally understand immunology and biology, experience the clinical and basic science needs and then apply their sound engineering, analytical and design skills to solve problems. On the other hand immunologists and clinical fellows need to be immersed in the engineering science, through partnership with their engineering colleagues, so that they can use these new tools and methods seamlessly. It is this true convergence of multiple experts that would allow us to advance human health. \u003Cbr \/\u003E\u003Cbr \/\u003EI am excited to be part of this tremendous effort that has brought together a public and a private university with a citizen-funded non-profit; a unique partnership that is rare in this country. We are off to a great start. Now, we have to deliver. There is much enthusiasm and expectation and we as engineers and scientists, immunologists and clinicians must keep in mind that at the end we are in it to help our fellow citizens; our children and parents, our friends and families and many others whom we have never met or will ever meet.\u003C\/p\u003E","summary":null,"format":"limited_html"}],"field_subtitle":[{"value":"Krishnendu Roy talks about the Center for Immunoengineering at Georgia Tech"}],"field_summary":[{"value":"\u003Cp\u003EKrishnendu Roy talks about the Center for Immunoengineering at Georgia Tech\u003C\/p\u003E","format":"limited_html"}],"field_summary_sentence":[{"value":"Krishnendu Roy talks about the Center for Immunoengineering at Georgia Tech"}],"uid":"27195","created_gmt":"2014-05-05 10:17:58","changed_gmt":"2016-10-08 03:16:22","author":"Colly Mitchell","boilerplate_text":"","field_publication":"","field_article_url":"","dateline":{"date":"2014-05-05T00:00:00-04:00","iso_date":"2014-05-05T00:00:00-04:00","tz":"America\/New_York"},"extras":[],"hg_media":{"242711":{"id":"242711","type":"image","title":"Krishnendu Roy, PhD","body":null,"created":"1449243704","gmt_created":"2015-12-04 15:41:44","changed":"1475894919","gmt_changed":"2016-10-08 02:48:39","alt":"Krishnendu Roy, PhD","file":{"fid":"197829","name":"roy_krish.jpg","image_path":"\/sites\/default\/files\/images\/roy_krish.jpg","image_full_path":"http:\/\/www.tlwarc.hg.gatech.edu\/\/sites\/default\/files\/images\/roy_krish.jpg","mime":"image\/jpeg","size":13278,"path_740":"http:\/\/www.tlwarc.hg.gatech.edu\/sites\/default\/files\/styles\/740xx_scale\/public\/images\/roy_krish.jpg?itok=l7uPtvh0"}}},"media_ids":["242711"],"related_links":[{"url":"http:\/\/www.immunoengineering.gatech.edu\/","title":"Immunoengineering website"},{"url":"http:\/\/www.immunoengineering-georgia.org\/","title":"Georgia ImmunoEngineering Consortium"}],"groups":[{"id":"1292","name":"Parker H. Petit Institute for Bioengineering and Bioscience (IBB)"}],"categories":[],"keywords":[],"core_research_areas":[{"id":"39441","name":"Bioengineering and Bioscience"}],"news_room_topics":[],"event_categories":[],"invited_audience":[],"affiliations":[],"classification":[],"areas_of_expertise":[],"news_and_recent_appearances":[],"phone":[],"contact":[{"value":"\u003Cp\u003E\u003Ca href=\u0022mailto:krishnendu.roy@bme.gatech.edu\u0022\u003EKrishnendu Roy, PhD\u003C\/a\u003E\u003Cbr \/\u003EDirector, Center for Immunoengineering at Georgia Tech\u003C\/p\u003E","format":"limited_html"}],"email":["krishnendu.roy@bme.gatech.edu"],"slides":[],"orientation":[],"userdata":""}},"279181":{"#nid":"279181","#data":{"type":"news","title":"Georgia ImmunoEngineering Consortium Aims to Improve Immune Response to Diseases","body":[{"value":"\u003Cp\u003EATLANTA\u2014A new research partnership between Emory University and the Georgia Institute of Technology will apply the principles of engineering to study the immune system and develop new therapies that can improve the immune response to diseases.\u003C\/p\u003E\u003Cp\u003EThe Georgia ImmunoEngineering Consortium (GIEC) will bring together engineers, physicians, chemists, physicists, computational scientists, immunologists and clinical investigators to better understand how the immune system works and how to precisely modulate it to target challenging diseases.\u003C\/p\u003E\u003Cp\u003EThe research teams will focus on cancer, infectious diseases, autoimmune and inflammatory disorders (diabetes, lupus, multiple sclerosis, arthritis, fibrosis, asthma, inflammatory bowel disease, etc.), and areas of regenerative medicine including transplantation, bone and cartilage repair, and treatments for spinal cord injuries.\u003C\/p\u003E\u003Cp\u003E\u201cThe immune system and its multi-faceted role in human health and disease form the cornerstone of medical research, says Ignacio Sanz, MD, co-chair of the consortium steering committee. Sanz is Mason I. Lowance Chair of Allergy and Immunology and director of the Lowance Center of Human Immunology at Emory, director of rheumatology in the Department of Medicine in Emory School of Medicine, and a Georgia Research Alliance Eminent Scholar.\u003C\/p\u003E\u003Cp\u003E\u201cThis consortium not only combines the expertise of researchers throughout a variety of disciplines focused on the human immune response, but also reflects an increasing focus on engineering technologies and informatics in improving the diagnosis and treatment of challenging diseases.\u201d\u003C\/p\u003E\u003Cp\u003E\u201cBy joining our immense strengths in immunology and bioengineering, we aspire to become an international leader in immunoengineering science; develop new technologies for prevention, rapid diagnosis, and treatment of immune-related disorders and train the next generation of physicians and engineers in this cutting edge research,\u201d says Krishnendu Roy, PhD, co-chair of the consortium steering committee, director of the Center for ImmunoEngineering in the Parker H. Petit Institute for Bioengineering and Bioscience at Georgia Tech and Carol Ann and David D. Flanagan professor of biomedical engineering in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003EImmunoengineering is the application of engineering tools and principles to better understand and monitor our immune system in health and in diseases. This knowledge is then used to develop more effective vaccines and therapies against a wide range of diseases like cancer, HIV, diabetes, multiple sclerosis, arthritis etc. and also to improve tissue regeneration, wound healing and transplantation, explain Sanz and Roy.\u003C\/p\u003E\u003Cp\u003E\u201cGame-changing innovation and world-class scholarship occur at the boundaries of fields of study where collaborators bring different perspectives to challenging problems,\u201d says Stephen E. Cross, executive vice president for research at Georgia Tech. \u201cThis is the essence of the successful 17-year partnership between engineering and science at Georgia Tech, and medical science and clinical practice at Emory.\u201d\u003C\/p\u003E\u003Cp\u003EExisting centers and departments that will collaborate within the new consortium include the Center for ImmunoEngineering at Georgia Tech as well as the Emory Vaccine Center, Lowance Center for Human Immunology, Departments of Medicine, Microbiology and Immunology, Hematology and Oncology, and Pathology and Laboratory Medicine in Emory School of Medicine, the Emory-Children\u2019s Pediatric Research Center, and Winship Cancer Institute, among others.\u003C\/p\u003E\u003Cp\u003EThe consortium has partnered with the Georgia Research Alliance (GRA), a nonprofit organization that expands research and commercialization capacity in Georgia\u2019s universities to launch new companies, create high-value jobs and transform lives.\u003C\/p\u003E\u003Cp\u003E\u201cThe Georgia ImmunoEngineering Consortium is a unique academic collaboration that represents strong opportunities to align our state\u2019s extensive university research base with targeted life sciences industry development in Georgia,\u201d says C. Michael Cassidy, GRA president and CEO. \u201cGRA looks forward to seeing the new discoveries and commercial opportunities that result from this partnership.\u201d\u003C\/p\u003E\u003Cp\u003EThe consortium will also collaborate with research partners at the Centers for Disease Control and Prevention (CDC) and partners at various colleges and universities around Georgia, the United States, and around the world.\u003C\/p\u003E\u003Cp\u003E\u201cUsing engineering approaches to help unlock the biology of the immune system opens the door for exciting new discoveries that can alter human disease,\u201d says David S. Stephens MD, vice president for research in Emory\u2019s Woodruff Health Sciences Center, chair of the Department of Medicine in Emory University School of Medicine, and a member of the consortium steering committee.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003EAdditional members of the steering committee from Georgia Tech include M.G. Finn and Susan Thomas, and from Emory include Rafi Ahmed and Edmund K. (Ned) Waller.\u003C\/p\u003E\u003Cp\u003EA symposium will celebrate the consortium launch:\u003C\/p\u003E\u003Cp\u003EGeorgia ImmunoEngineering Symposium: \u003Cbr \/\u003EFeb. 28, 2014, 7 a.m. \u2013 5 p.m.\u003Cbr \/\u003EEmory Conference Center\u003Cbr \/\u003E\u003Cbr \/\u003EFor more information about the consortium, please view the \u003Ca href=\u0022http:\/\/www.immunoengineering-georgia.org\/index.html\u0022\u003Ewebsite\u003C\/a\u003E.\u003C\/p\u003E\u003Cp\u003E- Holly Korschun, Emory University\u003C\/p\u003E","summary":null,"format":"limited_html"}],"field_subtitle":[{"value":"New research partnership between Emory and Georgia Tech will apply engineering principles to study the immune system"}],"field_summary":[{"value":"\u003Cp\u003ENew research partnership between Emory and Georgia Tech will apply engineering principles to study the immune system\u003C\/p\u003E","format":"limited_html"}],"field_summary_sentence":[{"value":"New research partnership between Emory and Georgia Tech will apply engineering principles to study the immune system"}],"uid":"27195","created_gmt":"2014-02-26 13:32:27","changed_gmt":"2016-10-08 03:15:55","author":"Colly Mitchell","boilerplate_text":"","field_publication":"","field_article_url":"","dateline":{"date":"2014-02-26T00:00:00-05:00","iso_date":"2014-02-26T00:00:00-05:00","tz":"America\/New_York"},"extras":[],"hg_media":{"279191":{"id":"279191","type":"image","title":"Georgia ImmunoEngineering Consortium","body":null,"created":"1449244168","gmt_created":"2015-12-04 15:49:28","changed":"1475894971","gmt_changed":"2016-10-08 02:49:31","alt":"Georgia ImmunoEngineering Consortium","file":{"fid":"198866","name":"gaimmunoengineering.jpg","image_path":"\/sites\/default\/files\/images\/gaimmunoengineering_0.jpg","image_full_path":"http:\/\/www.tlwarc.hg.gatech.edu\/\/sites\/default\/files\/images\/gaimmunoengineering_0.jpg","mime":"image\/jpeg","size":6357578,"path_740":"http:\/\/www.tlwarc.hg.gatech.edu\/sites\/default\/files\/styles\/740xx_scale\/public\/images\/gaimmunoengineering_0.jpg?itok=0VE5TmF7"}},"279201":{"id":"279201","type":"image","title":"Georgia ImmunoEngineering Consortium Image","body":null,"created":"1449244168","gmt_created":"2015-12-04 15:49:28","changed":"1475894971","gmt_changed":"2016-10-08 02:49:31","alt":"Georgia ImmunoEngineering Consortium Image","file":{"fid":"198867","name":"gaimmunoengineering2.jpg","image_path":"\/sites\/default\/files\/images\/gaimmunoengineering2_0.jpg","image_full_path":"http:\/\/www.tlwarc.hg.gatech.edu\/\/sites\/default\/files\/images\/gaimmunoengineering2_0.jpg","mime":"image\/jpeg","size":494024,"path_740":"http:\/\/www.tlwarc.hg.gatech.edu\/sites\/default\/files\/styles\/740xx_scale\/public\/images\/gaimmunoengineering2_0.jpg?itok=7_V4hKZI"}}},"media_ids":["279191","279201"],"related_links":[{"url":"http:\/\/www.immunoengineering-georgia.org\/index.html","title":"Georgia Immunoengineering website"}],"groups":[{"id":"1188","name":"Research Horizons"}],"categories":[{"id":"140","name":"Cancer Research"},{"id":"141","name":"Chemistry and Chemical Engineering"},{"id":"134","name":"Student and Faculty"},{"id":"146","name":"Life Sciences and Biology"},{"id":"149","name":"Nanotechnology and Nanoscience"},{"id":"135","name":"Research"}],"keywords":[{"id":"87781","name":"autoimmune"},{"id":"2305","name":"Emory University"},{"id":"9316","name":"immune system"},{"id":"1895","name":"Immunology"},{"id":"7243","name":"inflammatory"}],"core_research_areas":[{"id":"39441","name":"Bioengineering and Bioscience"}],"news_room_topics":[{"id":"71891","name":"Health and Medicine"}],"event_categories":[],"invited_audience":[],"affiliations":[],"classification":[],"areas_of_expertise":[],"news_and_recent_appearances":[],"phone":[],"contact":[{"value":"\u003Cp\u003EBrett Israel\u003C\/p\u003E\u003Cp\u003EResearch News\u003C\/p\u003E\u003Cp\u003E404-385-1933\u003C\/p\u003E\u003Cp\u003E\u003Ca href=\u0022mailto:brett.israel@comm.gatech.edu\u0022\u003Ebrett.israel@comm.gatech.edu\u003C\/a\u003E\u003C\/p\u003E","format":"limited_html"}],"email":["brett.israel@comm.gatech.edu"],"slides":[],"orientation":[],"userdata":""}},"254651":{"#nid":"254651","#data":{"type":"news","title":"Todd McDevitt and Krishnendu Roy Recognized for Breakthrough Research and Leadership  In Immunoengineering and Regenerative Medicine","body":[{"value":"\u003Cp\u003EThe University System of Georgia Board of Regents has approved the appointment of Krishnendu (Krish) Roy and Todd McDevitt to Carol Ann and David D. Flanagan Faculty Professorships in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University. \u0026nbsp;These appointments, generously endowed by the Flanagans in 2011, serve to recognize and reward faculty that are conducting high impact research and are exemplary citizens of the Wallace H. Coulter department and Georgia Tech as a whole. \u0026nbsp;Both Roy and McDevitt are bringing cutting-edge research and thought leadership to the burgeoning fields of immunoengineering and regenerative medicine.\u003C\/p\u003E\u003Cp\u003EMcDevitt is an associate professor in the Coulter Department, a Petit Faculty Fellow in the Petit Institute for Bioengineering and Bioscience, and director of the Stem Cell Engineering Center at Georgia Tech. The objective of McDevitt\u2019s research program is to develop enabling technologies for the directed differentiation of stem cells for regenerative medicine, disease models, and diagnostic applications. Much of his research focuses on the application of technologies to engineer stem cell fate, on stem cell bioprocessing and on engineering regenerative therapies from stem cells. McDevitt has garnered more than $9 million in funding, including a Transformative R01 award from the NIH and an NSF IGERT on Stem Cell Biomanufacturing. He received the 2010 Society for Biomaterials Young Investigator Award, a New Investigator Award from the American Heart Association and was recognized as one of the \u201c40 Under 40\u201d by \u003Cem\u003EGeorgia Trend\u003C\/em\u003E magazine. McDevitt graduated cum laude from Duke University, with a B.S.E. and a double major in Biomedical and Electrical Engineering. He received his Ph.D. in 2001 in Bioengineering from the University of Washington, where he worked for Patrick S. Stayton, and where he conducted post-doctoral research in the pathology laboratory of Charles E. Murry.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003ERoy joined the Coulter Department this summer as professor and is currently the director of the Center for Immunoengineering.\u0026nbsp; He is an elected Fellow of the American Institute for Medical and Biological Engineering (AIMBE) and a Fellow of the Biomedical Engineering Society (BMES). He received his B.S. from the Indian Institute of Technology, M.S. from Boston University and his Ph.D. in Biomedical Engineering from Johns Hopkins University. Following his Ph.D., he joined a start-up biotechnology company, Zycos Inc., where he served as a senior scientist in drug delivery research.\u0026nbsp; He joined The University of Texas at Austin in 2002, where most recently he was professor of Biomedical Engineering. He also served as the director of the graduate program and as associate chair for education and outreach. His research interests are in the areas of immunoengineering with particular focus on material-directed cells signaling and immune cell generation and controlled drug and vaccine delivery technologies with applications in cancer and immunotherapies.\u0026nbsp; Roy has received the Young Investigator Awards from The Society for Biomaterials (SFB) and the Controlled Release Society (CRS). He has been extensively funded by NIH, NSF, the Coulter Foundation, the Whitaker Foundation and the Cancer Prevention And Research Institute of Texas, among others. He serves as a member of the editorial boards for the Journal of Controlled Release and the European Journal of Pharmaceutics and Biopharmaceutics.\u003C\/p\u003E\u003Cp\u003EGeorgia Tech and Emory created the joint department of biomedical engineering in the fall of 1997. The collaborative relationship blends the expertise of medical researchers at the Emory University School of Medicine with that of the engineering faculty at Georgia Tech, and is the first of its kind between a public and private institution. The collaboration has resulted in a biomedical engineering program that consistently ranks among the top five in the nation by\u003Cem\u003E U.S. News \u0026amp; World Report.\u003C\/em\u003E\u003C\/p\u003E","summary":null,"format":"limited_html"}],"field_subtitle":[{"value":"Flanagans Support Novel, High-Impact Biomedical Research with Endowment"}],"field_summary":[{"value":"\u003Cp\u003EThe University System of Georgia Board of Regents has approved the appointment of Krishnendu (Krish) Roy and Todd McDevitt to Carol Ann and David D. Flanagan Faculty Professorships in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University. \u0026nbsp;These appointments, generously endowed by the Flanagans in 2011, serve to recognize and reward faculty that are conducting high impact research and are exemplary citizens of the Wallace H. Coulter department and Georgia Tech as a whole. \u0026nbsp;Both Roy and McDevitt are bringing cutting-edge research and thought leadership to the burgeoning fields of immunoengineering and regenerative medicine.\u003C\/p\u003E","format":"limited_html"}],"field_summary_sentence":[{"value":"The University System of Georgia Board of Regents has approved the appointment of Krishnendu (Krish) Roy and Todd McDevitt to Carol Ann and David D. Flanagan Faculty Professorships in the Wallace H. Coulter Department of Biomedical Engineering."}],"uid":"27182","created_gmt":"2013-11-14 15:15:41","changed_gmt":"2016-10-08 03:15:22","author":"Adrianne Proeller","boilerplate_text":"","field_publication":"","field_article_url":"","dateline":{"date":"2013-11-14T00:00:00-05:00","iso_date":"2013-11-14T00:00:00-05:00","tz":"America\/New_York"},"extras":[],"hg_media":{"243221":{"id":"243221","type":"image","title":"Dr. Krishnendu Roy","body":null,"created":"1449243704","gmt_created":"2015-12-04 15:41:44","changed":"1475894919","gmt_changed":"2016-10-08 02:48:39","alt":"Dr. Krishnendu Roy","file":{"fid":"197851","name":"roy-agarwal_0.jpg","image_path":"\/sites\/default\/files\/images\/roy-agarwal_0_0.jpg","image_full_path":"http:\/\/www.tlwarc.hg.gatech.edu\/\/sites\/default\/files\/images\/roy-agarwal_0_0.jpg","mime":"image\/jpeg","size":88915,"path_740":"http:\/\/www.tlwarc.hg.gatech.edu\/sites\/default\/files\/styles\/740xx_scale\/public\/images\/roy-agarwal_0_0.jpg?itok=4Esyg2Dq"}},"254661":{"id":"254661","type":"image","title":"Todd McDevitt","body":null,"created":"1449243828","gmt_created":"2015-12-04 15:43:48","changed":"1475894934","gmt_changed":"2016-10-08 02:48:54","alt":"Todd McDevitt","file":{"fid":"198186","name":"todd_mcdevitt_lab.jpg","image_path":"\/sites\/default\/files\/images\/todd_mcdevitt_lab_0.jpg","image_full_path":"http:\/\/www.tlwarc.hg.gatech.edu\/\/sites\/default\/files\/images\/todd_mcdevitt_lab_0.jpg","mime":"image\/jpeg","size":4014690,"path_740":"http:\/\/www.tlwarc.hg.gatech.edu\/sites\/default\/files\/styles\/740xx_scale\/public\/images\/todd_mcdevitt_lab_0.jpg?itok=TebBWi34"}}},"media_ids":["243221","254661"],"related_links":[{"url":"http:\/\/www.bme.gatech.edu\/facultystaff\/faculty_record.php?id=173","title":"Krishnendu Roy"},{"url":"http:\/\/www.bme.gatech.edu\/facultystaff\/faculty_record.php?id=78","title":"Todd McDevitt"}],"groups":[{"id":"1254","name":"Wallace H. Coulter Dept. of Biomedical Engineering"}],"categories":[{"id":"129","name":"Institute and Campus"},{"id":"42941","name":"Art Research"},{"id":"140","name":"Cancer Research"},{"id":"146","name":"Life Sciences and Biology"},{"id":"135","name":"Research"}],"keywords":[{"id":"249","name":"Biomedical Engineering"},{"id":"5775","name":"Bioscience Research"},{"id":"25821","name":"Georgia Tech \u0026 Emory Center for Regenerative Medicine (GTEC)"},{"id":"73511","name":"immunoengineering"},{"id":"75821","name":"Immunoengineering Center"},{"id":"167130","name":"Stem Cells"}],"core_research_areas":[{"id":"39441","name":"Bioengineering and Bioscience"}],"news_room_topics":[],"event_categories":[],"invited_audience":[],"affiliations":[],"classification":[],"areas_of_expertise":[],"news_and_recent_appearances":[],"phone":[],"contact":[{"value":"\u003Cp\u003EAdrianne Proeller\u003C\/p\u003E","format":"limited_html"}],"email":["adrianne.proeller@bme.gatech.edu"],"slides":[],"orientation":[],"userdata":""}},"242701":{"#nid":"242701","#data":{"type":"news","title":"Georgia Tech Launches New Immunoengineering Center","body":[{"value":"\u003Cp\u003EMore than 15 faculty from seven different schools and departments join together to form the new Center for Immunoengineering at Georgia Tech.\u0026nbsp; This new effort brings biomedical engineers, bioengineers, chemical engineers, chemists, biologists and mechanical engineers together to encourage new innovative approaches to study the immune system and to assess, predict and control immune response. \u003Cbr \/\u003E\u003Cbr \/\u003EKrish Roy, PhD, professor in the Wallace H. Coulter Department of Biomedical Engineering and faculty member of the Parker H. Petit Institute for Bioengineering and Bioscience (Petit Institute), will head the new center. \u003Cbr \/\u003E\u003Cbr \/\u003EThe mission of the Immunoengineering Research Center is to develop breakthrough engineering tools and methods for personalized and predictive health care of patients. The center will focus on three grand challenges: ability to rapidly provide a comprehensive immunological status of a patient, to quantitatively predict immune function in a patient and to precisely modulate and control the immune response of a patient. \u0026nbsp;\u003Cbr \/\u003E\u003Cbr \/\u003E\u201cThe center will facilitate integration between Georgia Tech researchers and partner institutions including Emory University and its various immunology and vaccine centers,\u201d Roy explained.\u0026nbsp; \u0026nbsp;\u003Cbr \/\u003E\u003Cbr \/\u003EIn addition to Roy, the center will be led by a faculty executive committee which includes, M.G. Finn, professor, school of Chemistry and Biochemistry, Susan Thomas, assistant professor, George W. Woodruff School of Mechanical Engineering and associate professors, Julia Babensee and Melissa Kemp and Cheng Zhu, professor from biomedical engineering. \u0026nbsp;\u003Cbr \/\u003E\u003Cbr \/\u003E\u201cDeveloping engineering technologies to modulate the immune system is critical to manage autoimmune disorders like multiple sclerosis and type I diabetes, as well as to address immunodeficiencies,\u201d Ravi Bellamkonda, chair of the biomedical engineering department, stated. \u201cIt is increasingly apparent that the immune system also plays an important role in regeneration of injured tissues and therefore immunoengineering can have a broad and significant impact on human health.\u201d\u003Cbr \/\u003E\u003Cbr \/\u003ENew mechanistic methods based on engineering principles are being developed which in recent years have lead to tremendous strides in the development of potential therapeutics and the identification of new vaccine design, better biomaterials, as well as new avenues for commercialization and clinical translation. \u003Cbr \/\u003E\u003Cbr \/\u003E\u0026nbsp;\u201cThere is tremendous opportunity in bringing this group of researchers together under the immunoengineering umbrella,\u201d Robert Guldberg, executive director of the Petit Institute, said. \u201cThis new center will bring together researchers from a wide-variety of backgrounds to tackle complex research problems in new and exciting ways.\u201d \u003Cbr \/\u003E\u003Cbr \/\u003E\u003Cbr \/\u003E\u003C\/p\u003E","summary":null,"format":"limited_html"}],"field_subtitle":[{"value":"Includes more than 15 faculty from seven different GT schools \u0026 departments"}],"field_summary":[{"value":"\u003Cp\u003EGeorgia Tech Launches New Immunoengineering Center - Includes more than 15 faculty from seven different GT schools \u0026amp; departments\u003C\/p\u003E","format":"limited_html"}],"field_summary_sentence":[{"value":"Includes more than 15 faculty from seven different GT schools \u0026 departments"}],"uid":"27195","created_gmt":"2013-10-04 10:52:05","changed_gmt":"2016-10-08 03:15:00","author":"Colly Mitchell","boilerplate_text":"","field_publication":"","field_article_url":"","dateline":{"date":"2013-10-04T00:00:00-04:00","iso_date":"2013-10-04T00:00:00-04:00","tz":"America\/New_York"},"extras":[],"hg_media":{"242711":{"id":"242711","type":"image","title":"Krishnendu Roy, PhD","body":null,"created":"1449243704","gmt_created":"2015-12-04 15:41:44","changed":"1475894919","gmt_changed":"2016-10-08 02:48:39","alt":"Krishnendu Roy, PhD","file":{"fid":"197829","name":"roy_krish.jpg","image_path":"\/sites\/default\/files\/images\/roy_krish.jpg","image_full_path":"http:\/\/www.tlwarc.hg.gatech.edu\/\/sites\/default\/files\/images\/roy_krish.jpg","mime":"image\/jpeg","size":13278,"path_740":"http:\/\/www.tlwarc.hg.gatech.edu\/sites\/default\/files\/styles\/740xx_scale\/public\/images\/roy_krish.jpg?itok=l7uPtvh0"}}},"media_ids":["242711"],"related_links":[{"url":"http:\/\/www.ibb.gatech.edu\/","title":"Petit Institute for Bioengineering and Bioscience"},{"url":"http:\/\/roylab.gatech.edu\/roy\/index.html","title":"Roy lab website"}],"groups":[{"id":"1292","name":"Parker H. Petit Institute for Bioengineering and Bioscience (IBB)"}],"categories":[{"id":"134","name":"Student and Faculty"}],"keywords":[{"id":"75821","name":"Immunoengineering Center"}],"core_research_areas":[{"id":"39441","name":"Bioengineering and Bioscience"}],"news_room_topics":[],"event_categories":[],"invited_audience":[],"affiliations":[],"classification":[],"areas_of_expertise":[],"news_and_recent_appearances":[],"phone":[],"contact":[{"value":"\u003Cp\u003E\u003Ca href=\u0022mailto:mcdevitt@ibb.gatech.edu\u0022\u003EMegan McDevitt\u003C\/a\u003E\u003C\/p\u003E\u003Cp\u003EParker H. Petit Institute for Bioengineering \u0026amp; Bioscience\u003C\/p\u003E","format":"limited_html"}],"email":["mcdevitt@ibb.gatech.edu"],"slides":[],"orientation":[],"userdata":""}}}